

Supplement to:

Clinical Pharmacogenetics Implementation Consortium Guideline for *CYP2D6* and *CYP2C19* Genotypes and Dosing of Tricyclic Antidepressants

J. Kevin Hicks¹, Jesse J. Swen², Caroline F. Thorn³, Katrin Sangkuhl³, Evan D. Kharasch⁴, Vicki L. Ellingrod^{5,6}, Todd C. Skaar⁷, Daniel J. Müller⁸, Andrea Gaedigk⁹, and Julia C. Stingl¹⁰

¹Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA

²Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands

³Department of Genetics, Stanford University, Stanford, California, USA

⁴Division of Clinical and Translational Research, Department of Anesthesiology, Washington University in St. Louis, St. Louis, Missouri, USA

⁵Department of Clinical, Social and Administrative Sciences, College of Pharmacy, and Department of Psychiatry, School of Medicine, University of Michigan, Ann Arbor, Michigan, USA

⁶Department of Psychiatry, School of Medicine, University of Michigan, Ann Arbor, Michigan, USA

⁷Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA

⁸Neurogenetics Section, Centre for Addiction and Mental Health, and Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada

⁹Division of Pediatric Pharmacology and Medical Toxicology, Children's Mercy Hospital & Clinics, Kansas City, Missouri, USA

¹⁰Division of Research, Federal Institute for Drugs and Medical Devices, University of Bonn Medical Faculty, Bonn, Germany

Corresponding Author: Julia C. Stingl, MD
Chair Research Division
Federal Institute for Drugs and Medical Devices
Professor of Translational Pharmacology
Kurt-Georg-Kiesinger-Allee 3
D-53175 Bonn, Germany
Phone: +49 (0)228-99-307-3570
cpic@pharmgkb.org

Table of Content

| | |
|--|----|
| Introduction..... | 4 |
| Supplemental Table S1: Frequencies of <i>CYP2D6</i> alleles in major race/ethnic groups | 11 |
| Supplemental Table S2: Frequencies of <i>CYP2C19</i> alleles in major race/ethnic groups | 14 |
| Supplemental Table S3: Commonly tested polymorphisms defining <i>CYP2D6</i> variant alleles and their effect on CYP2D6 protein | 15 |
| Supplemental Table S4: Association between allelic variants and CYP2D6 enzyme activity | 17 |
| Supplemental Table S5: Commonly tested polymorphisms defining <i>CYP2C19</i> variant alleles and their effect on CYP2C19 protein | 18 |
| Supplemental Table S6: Association between allelic variants and CYP2C19 enzyme activity ... | 19 |
| Supplemental Table S7: Examples of <i>CYP2D6</i> genotypes with resulting activity scores and phenotype classification | 20 |
| Supplemental Table S8: Predicted metabolizer phenotypes based on <i>CYP2D6</i> diplotypes | 21 |
| Supplemental Table S9: Predicted metabolizer phenotypes based on <i>CYP2C19</i> diplotypes | 22 |
| Supplemental Table S10: Tricyclic antidepressant metabolism by CYP2D6 and CYP2C19 | 23 |
| Supplemental Table S11: Tricyclic antidepressant side effects | 24 |
| Supplemental Table S12: Evidence linking CYP2D6 and/or CYP2C19 phenotype or genotype with amitriptyline metabolism or response | 26 |
| Supplemental Table S13: Evidence linking CYP2D6 phenotype or genotype with nortriptyline metabolism or response | 29 |
| Supplemental Table S14: Evidence linking CYP2D6 and/or CYP2C19 phenotype or genotype with clomipramine metabolism or response | 31 |
| Supplemental Table S15: Evidence linking CYP2D6 phenotype or genotype with desipramine metabolism or response | 33 |
| Supplemental Table S16: Evidence linking CYP2D6 and/or CYP2C19 phenotype or genotype with doxepin metabolism or response | 35 |
| Supplemental Table S17: Evidence linking CYP2D6 and/or CYP2C19 phenotype or genotype with imipramine metabolism or response | 36 |

| | |
|---|----|
| Supplemental Table S18: Evidence linking CYP2D6 and/or CYP2C19 phenotype or genotype with trimipramine metabolism or response | 39 |
| Supplemental Table S19: Dosing recommendations for amitriptyline based on both CYP2D6 and CYP2C19 phenotype | 40 |
| References | 42 |

INTRODUCTION

Guideline Updates

The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for *CYP2D6* and *CYP2C19* genotypes and the dosing of tricyclic antidepressants is published in full on the PharmGKB website (www.pharmgkb.org).¹ Relevant information will be reviewed periodically and updated guidelines published online.

Literature Review

We searched the PubMed® database (1966 to September 2012) for the following keywords: (cytochrome P450 2D6 or CYP2D6) OR (cytochrome P450 2C19 or CYP2C19) AND (tricyclic antidepressants OR amitriptyline OR clomipramine OR desipramine OR doxepin OR imipramine OR nortriptyline OR trimipramine) for the association between *CYP2D6* and/or *CYP2C19* genotypes and metabolism of tricyclic antidepressant drugs or tricyclic antidepressant-related adverse drug events or clinical outcomes. For key publications pertaining to clinical pharmacogenetic studies on tricyclic antidepressant response or adverse effects, and reviews or consensus statements, see references.²⁻⁶

The *CYP2D6* and *CYP2C19* allele frequency tables are based on previously published CPIC guidelines.^{7,8} Updates to the *CYP2D6* allele frequency table were made by searching the PubMed® database (1995 to June 2012) using the following key words: CYP2D6, CYP 2D6, cytochrome P4502D6, ethnic, ethnicity, race, population, and names of countries and populations (e.g., Spain, Spanish, Brazil, Brazilian). In addition, reports were also identified from citations by others or review articles. Studies were considered for inclusion if: (1) the ethnicity of the population was clearly indicated, (2) either *CYP2D6* allele frequencies or genotype frequencies were reported, (3) the method by which *CYP2D6* was genotyped was indicated, (4) the sample population consisted of at least 50 individuals with a few exceptions (e.g., smaller cohorts that were part of larger studies) and (5) the study represented an original publication (no reviews or meta-analyses).

Genes: *CYP2D6* and *CYP2C19*

Genetic Test Interpretation. *CYP2D6* and *CYP2C19* genetic variants are typically reported as haplotypes, which are defined by a specific combination of single nucleotide polymorphisms (SNPs) and/or other sequence variations including insertions and deletions that are interrogated during genotyping analysis. *CYP2D6* and *CYP2C19* haplotypes are assigned a star-allele nomenclature to allow for the standardization of genetic polymorphism annotation.⁹ A complete list of *CYP2D6* and *CYP2C19* star-allele nomenclature along with the genetic variants that define each star-allele are available at <http://www.cypalleles.ki.se/cyp2d6.htm> and <http://www.cypalleles.ki.se/cyp2c19.htm>, respectively. Information regarding *CYP2D6* or *CYP2C19* haplotypes (star-alleles) is also available at PharmGKB (www.pharmgkb.org).¹ Knowing which SNPs or other genetic variants a particular test analyzes for is important. The

inclusion or exclusion of certain genetic variants in a pharmacogenetic test could affect the reported result.

Reference laboratories usually report a diplotype, which is the summary of inherited maternal and paternal star-alleles (e.g., *CYP2C19**1/*2, where the patient inherited a *1 allele and a *2 allele). Commonly reported *CYP2D6* and *CYP2C19* star-alleles are categorized into functional groups (e.g., functional, reduced function, or non-functional) based on the predicted activity of the encoded enzyme (Supplementary Tables S4 and S6). The predicted phenotype (Supplementary Tables S7-9) is influenced by the expected function of each reported allele in the diplotype. Phenotype-predicting tools including “look-up” or “translation” tables are being developed by the Translational Pharmacogenetics Project group and can be accessed at www.pharmgkb.org.¹ Hicks *et al.* describes the development of the *CYP2D6* look-up table.¹⁰

Phenotyping CYP2D6 and CYP2C19. The tricyclic antidepressants were considered a first-line treatment option for depression during the 1960s and 1970s, but their use started to decline in the 1980s as new drugs with fewer side effects were developed to treat depression.¹¹ Much knowledge about the tricyclics was gained during the height of their use, a time in which genotyping studies were mostly nonexistent. However, valuable information about how *CYP2D6* or *CYP2C19* metabolizer status affects pharmacokinetic properties and outcomes was acquired by phenotyping patients for *CYP2D6* or *CYP2C19* enzyme function. Probe drugs including dextromethorphan, sparteine, and debrisoquine were used for *CYP2D6* phenotyping, while proguanil and mephenytoin were used for *CYP2C19* phenotyping.¹²⁻¹⁵ The proton pump inhibitors have replaced proguanil and mephenytoin as the preferred probes for phenotyping *CYP2C19*. Omeprazole is an established *CYP2C19* probe in adults, but pantoprazole may be a more suitable choice for *CYP2C19* phenotyping in pediatric patients.^{16,17} In most instances patients were divided into two groups, either poor or extensive metabolizers. Good concordance has been observed between assigned phenotypes based on probe drugs and genetic test results.¹⁸⁻²⁴ Therefore, we consider outcome and pharmacokinetic data obtained from studies where individuals were phenotyped to be comparable to outcome and pharmacokinetic data obtained from studies where individuals were genotyped.

Calculating CYP2D6 Activity Score. Gaedigk *et al.* developed a scoring system to provide a uniform approach to assigning a predicted *CYP2D6* phenotype.²⁵ *CYP2D6* alleles are assigned an activity value as detailed in Supplementary Table S4. The activity value of each allele reported in the diplotype is added together to calculate the *CYP2D6* activity score. For example, to calculate the activity score of a *CYP2D6**1/*17 diplotype, the activity value of *1 (activity value = 1) and the activity value of *17 (activity value = 0.5) are totaled to provide the *CYP2D6* activity score of 1.5. For this guideline the *CYP2D6* activity score is used to assign a predicted phenotype as follows: activity score of 0 = poor metabolizer, activity score of 0.5 = intermediate metabolizer, activity scores ranging from 1.0-2.0 = extensive metabolizer, and activity score greater than 2.0 = ultrarapid metabolizer. Therefore, a pharmacogenetic test result of *CYP2D6**1/*17 would result in a *CYP2D6* activity score of 1.5 and a predicted phenotype of extensive metabolizer.

CYP2D6 Copy Number Variations. Because *CYP2D6* is subject to copy number variations (gene duplications, multiplications, or deletions), reference laboratories may report gene copy number. Most patients will have a copy number of 2, with one allele inherited maternally and one allele inherited paternally. When two *CYP2D6* gene copies are present, the diplotype may be reported as follows: *CYP2D6**1/*1 or *CYP2D6* (*1/*1)2N, where “2” represents copy number. A copy number of “1” indicates the presence of a single *CYP2D6* gene deletion, and a copy number of “0” indicates both *CYP2D6* genes are deleted. *CYP2D6* gene deletions are indicated by the *5 allele. A gene deletion that is present on one chromosome may be reported as follows: *CYP2D6**2/*5 or *CYP2D6* (*2/*2)1N, where “1” represents copy number and the *5 allele is inferred. Typically, reference laboratories will report two gene deletions as *CYP2D6**5/*5 or *CYP2D6* (*5/*5)0N.

A copy number greater than two indicates the presence of a *CYP2D6* gene duplication or multiplication. When a *CYP2D6* gene duplication is present, the diplotype may be reported as *CYP2D6* (*1/*2)3N, where “3” represents copy number. A reference laboratory may not report an exact copy number, but rather indicate that additional copies of the *CYP2D6* gene are present (e.g., *CYP2D6**1/*2 duplication). In instances where a duplication is present and the exact copy number is not reported, most patients will likely have a *CYP2D6* copy number of 3. However, individuals carrying as many as 13 *CYP2D6* copies have been reported.²⁶ Reference laboratories usually do not determine which allele is duplicated, therefore when calculating *CYP2D6* activity score the duplication must be considered for each allele reported in the diplotype.²⁷ For example, a genotype result of *CYP2D6* (*1/*4)3N indicates a patient has three copies of the *CYP2D6* gene, with either two copies of the *1 allele and one copy of the *4 allele, or one copy of the *1 allele and two copies of the *4 allele. If the *1 allele carries the duplication the *CYP2D6* activity score of this diplotype will be 2, whereas if the *4 allele carries the duplication, the activity score will be 1. Studies have been published describing the translation of *CYP2D6* genotypes into predicted phenotypes when gene duplications or multiplications are present.^{8,10,25,27}

CYP2D6 Other Considerations. There are several factors that cause potential uncertainty in *CYP2D6* genotyping results and phenotype predictions as follows: **1)** Because it is currently impractical to test for every variation in the *CYP2D6* gene, genotyping assays may not detect rare or *de novo* variants resulting in patients being assigned a default genotype. Depending on the sequence variations (or alleles present) in a given patient, the default genotype may be *CYP2D6**1/*1 (or wild-type) or another diplotype. If the rare or *de novo* variant adversely affects *CYP2D6* enzyme function, then the patient’s actual phenotype may differ from the predicted phenotype. **2)** Sub-alleles of *CYP2D6**4 have been identified that harbor additional SNPs with limited or no added functional consequence (e.g., *CYP2D6**4A, *4B, *4C, and *4D). Therefore, only analyzing for the defining *CYP2D6**4 SNPs (100C>T and 1846G>A) is usually sufficient to determine a *CYP2D6* phenotype. **3)** There are multiple gene units involved in duplication and other major rearrangements. Additionally, the pseudogenes *CYP2D7* and *CYP2D8* may be misinterpreted as functional duplications.²⁸ If the specific gene units involved in the duplication or other rearrangements are not specifically tested for, the phenotype prediction may be inaccurate and *CYP2D6* activity over-estimated. **4)** Some SNPs exist on multiple alleles. For

example, *CYP2D6**69 carries the defining SNPs for *CYP2D6**41 (2850C>T, 2988G>A, and 4180G>C) and the defining SNPs for *CYP2D6**10 (100C>T and 4180G>C) in addition to multiple other SNPs. If a patient carries these genetic variants (in the absence of 1846G>A), a *CYP2D6**10/*41 diplotype is typically assigned, because this is the most likely result based on allele frequencies. However, a *CYP2D6**1/*69 genotype cannot be excluded with certainty. Testing for additional SNPs (e.g., 1062A>G, 3384A>C, and 3584G>A) could exclude *CYP2D6**1/*69 with certainty. Therefore, to unequivocally determine the presence of certain alleles, testing for multiple SNPs may be required. **5)** Allele frequencies may vary considerably among individuals of different ethnic backgrounds. For instance, *CYP2D6**10 is common in Asian populations while *CYP2D6**17 is common in people of Sub-Saharan African ancestry. These alleles, however, have a considerably lower prevalence in other ethnic groups such as Caucasians of European ancestry. As another example, *CYP2D6**14A is present in Asian populations and therefore its defining SNP (1758G>A) has been incorporated into Asian genotyping panels.²⁹ Thus, the alleles that should be tested for a given population may vary considerably. **6)** Certain alleles carry genes in tandem arrangements. One such example is *CYP2D6**36+*10 (one copy of the non-functional *CYP2D6**36 and one copy of the reduced function *CYP2D6**10). This tandem can be found in Asian populations and is typically reported as a default assignment of *CYP2D6**10.

Available CYP2D6 Genetic Test Options. Commercially available genetic testing options change over time. Additional information about pharmacogenetic testing can be found at <http://www.pharmgkb.org> or the Genetic Testing Registry found at <http://www.ncbi.nlm.nih.gov/gtr/>.¹ The American College of Medical Genetics and Genomics (ACMG) established guidelines for laboratory testing of *CYP2D6* in relation to tamoxifen therapy.³⁰ The following list provides a selection of different platforms that are currently available for *CYP2D6* genotyping, some of which are approved by the U.S. Food and Drug Administration. It should be noted that some platforms may not include an assessment of *CYP2D6* copy number and thus cannot adequately predict *CYP2D6* phenotype.

1. AmpliChip® CYP450 Test (Roche Molecular Systems, Inc., Pleasanton, CA)³¹⁻³³
2. xTAG® CYP2D6 (Luminex® Molecular Diagnostics, Toronto, ON, Canada)³²
3. INFINITI® CYP450 2D6 (AutoGenomics, Inc., Vista, CA)³²
4. DMET™ (Affymetrix, Inc., Santa Clara, CA)³⁴
5. VeraCode® ADME Core Panel (Illumina, Inc., San Diego, CA)³⁵
6. TaqMan® Drug Metabolism Genotyping Assay Sets (Applied Biosystems, Inc., Foster City, CA)^{36,37}

Clinical genotyping services for *CYP2D6* are available from multiple reference laboratories. Several examples are listed below.

1. LabCorp Laboratory Corporation of America®
2. Quest Diagnostics®
3. Mayo Medical Laboratories

4. ARUP®

5. PG_{XL}[™] Laboratories

Reference laboratories may analyze for different SNPs or other genetic variants, which are dependent on the genotyping platform used and may affect the reported diplotype leading to discrepant results between methodologies. Additionally, reference laboratories may differ in how *CYP2D6* copy number variations are reported, which can potentially affect phenotype prediction. Therefore, it is important to know the genetic variants analyzed by each reference laboratory and how copy number variants are reported. Reference laboratories may give an interpretation of the *CYP2D6* genotype result and provide a predicted *CYP2D6* phenotype. Phenotype assignment for this guideline is defined in the main manuscript and supplementary data, but may differ from reference laboratory interpretations. If the genotyping results will be reported in a patient's medical record, reference laboratories will need to implement genotyping platforms using CLIA standards.

CYP2C19 Other Considerations. There are several factors to consider when genotyping *CYP2C19*. Some of these factors may cause potential uncertainty in *CYP2C19* genotyping results and phenotype predictions and are listed as follows: **1)** *CYP2C19*2* is the most common loss-of-function allele. Sub-alleles of *CYP2C19*2* have been identified that harbor additional SNPs with limited or no added functional consequence (e.g., *CYP2C19*2A*, **2B*, **2C*, and **2D*). Therefore, only analyzing for the defining *CYP2C19*2* SNP (c.681G>A) is usually sufficient to determine a *CYP2C19* phenotype. **2)** Because it is currently impractical to test for every variation in the *CYP2C19* gene, genotyping assays may not detect rare or *de novo* variants. Depending on the sequence variations (or alleles present) in a given patient, the default genotype may be *CYP2C19*1/*1* (or wild-type) or another diplotype. If the rare or *de novo* variant adversely affects *CYP2C19* enzyme function, then the patient's actual phenotype may differ from the predicted phenotype. **3)** *CYP2C19* allele frequencies may vary considerably among individuals of different ethnic backgrounds. *CYP2C19*3* has a low prevalence among most ethnic groups, but has an allele frequency of approximately 15% in some Asian populations (Supplemental Table S2).⁷ Thus, the alleles that should be tested for a given population may vary considerably. For Asian populations, *CYP2C19*3* analysis should be included in a *CYP2C19* genotyping panel. **4)** The defining polymorphisms for *CYP2C19*2* (c.681G>A) and *CYP2C19*17* (c.-806C>T) are in linkage disequilibrium with each other.⁷ Therefore, it is difficult to determine whether these two variants function independently of each other. Published articles focusing on clopidogrel argue both for³⁸ and against^{39,40} independence. **5)** The *CYP2C19*4* loss-of-function allele has been identified in linkage disequilibrium with *CYP2C19*17* (c.-806C>T) in certain ethnic subpopulations and this haplotype is designated *CYP2C19*4B*.^{7,41} *CYP2C19*17* is a gain-of-function allele, while *CYP2C19*4B* is a loss-of-function allele. Probing for *CYP2C19*4* in addition to *CYP2C19*17* may improve *CYP2C19* phenotype prediction accuracy. **6)** Certain genotyping platforms (e.g., Affymetrix DMET) analyze for over 15 *CYP2C19* star-alleles, many of which are rare and not well characterized. Therefore, uncertainty exists when translating a genotype result into a predicted *CYP2C19* phenotype in instances where a patient is found to carry a poorly characterized allele.

Available CYP2C19 Genetic Test Options. Commercially available genetic testing options change over time. Additional information about pharmacogenetic testing can be found at <http://www.pharmgkb.org> or the Genetic Testing Registry found at <http://www.ncbi.nlm.nih.gov/gtr/>.¹ Some clinical laboratories perform *CYP2C19* testing using analyte-specific reagents as in-house validated Laboratory Developed Tests (LDTs).⁷ Clinical trials are underway investigating *CYP2C19* point-of-care genetic testing.⁴² A number of different platforms are currently available for *CYP2C19* genotyping. The following list provides a selection of different platforms that are currently available, some of which are approved by the U.S. Food and Drug Administration.

1. AmpliChip® CYP450 Test (Roche Molecular Systems, Inc., Pleasanton, CA)³¹⁻³³
2. INFINITI® CYP2C19 Assay (AutoGenomics, Inc., Vista, CA)^{32,43}
3. DMET™ (Affymetrix, Inc., Santa Clara, CA)^{34,44}
4. eSensor® 2C19 Test (GenMark Diagnostics, Inc., Carlsbad, CA)⁴³
5. TaqMan® Drug Metabolism Genotyping Assay Sets (Applied Biosystems, Inc., Foster City, CA)^{32,45}
6. SNPlex Genotyping System (Applied Biosystems, Inc., Foster City, CA)^{37,46,47}
7. VeraCode® ADME Core Panel (Illumina, Inc., San Diego, CA)³⁵

Clinical genotyping services for *CYP2C19* are available from multiple reference laboratories. Several examples are listed below.

1. LabCorp Laboratory Corporation of America®
2. Quest Diagnostics®
3. Mayo Medical Laboratories
4. ARUP®
5. PG_{xL}™ Laboratories

Reference laboratories may analyze for different SNPs or other genetic variants, which are dependent on the genotyping platform used and may affect the reported diplotype leading to discrepant results between methodologies. Therefore, it is important to know the genetic variants analyzed for by each reference laboratory. Reference laboratories may give an interpretation of the *CYP2C19* genotype result and provide a predicted *CYP2C19* phenotype. Phenotype assignment for this guideline is defined in the main manuscript and supplementary data, but may differ from reference laboratory interpretations. If the genotyping results will be reported in a patient's medical record, reference laboratories will need to implement genotyping platforms using CLIA standards.

Levels of Evidence

The evidence summarized in Supplemental Tables S12-18 is graded using a scale based on previously published criteria⁴⁸ that was applied to other CPIC guidelines^{7,8,49-52} as follows:

- **High:** Evidence includes consistent results from well-designed, well-conducted studies.

- **Moderate:** Evidence is sufficient to determine effects, but the strength of the evidence is limited by the number, quality, or consistency of the individual studies; generalizability to routine practice; or indirect nature of the evidence.
- **Weak:** Evidence is insufficient to assess the effects on health outcomes because of limited number or power of studies, important flaws in their design or conduct, gaps in the chain of evidence, or lack of information.

Every effort was made to present evidence from high-quality original research studies. In addition, we took into consideration all available peer-reviewed published literature including other gene-based dosing recommendations.²⁻⁶ This literature provided the framework for the strength of therapeutic recommendations.

Strength of Therapeutic Recommendations

CPIC's therapeutic recommendations are based on weighting the evidence from a combination of preclinical functional and clinical data, as well as on some existing disease-specific consensus guidelines. Some of the factors that are taken into account in evaluating the evidence supporting therapeutic recommendations include: *in vivo* pharmacokinetic and pharmacodynamic data, *in vitro* enzyme activity of tissues expressing wild-type or variant-containing CYP2D6 or CYP2C19, *in vitro* CYP2D6 or CYP2C19 enzyme activity from tissues isolated from individuals of known *CYP2D6* or *CYP2C19* genotypes, and *in vivo* pre-clinical and clinical pharmacokinetic and pharmacodynamic studies. The gene-based dosing recommendations in this guideline takes into consideration the effects *CYP2D6* or *CYP2C19* genetic variants may have on both clinical outcomes and tricyclic plasma concentrations. Because the pharmacokinetic properties of tricyclic antidepressants do not differ between healthy volunteers and patients, we evaluated pharmacokinetic data acquired from studies performed on healthy subjects and patients to assist us in determining if *CYP2D6* or *CYP2C19* genetic variants affect tricyclic plasma concentrations.

The therapeutic recommendations are simplified to allow rapid interpretation by clinicians. They have been adopted from the rating scale for evidence-based therapeutic recommendations on the use of retroviral agents found at <http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf>.^{53,54} The recommendations are as follows:

- Strong recommendation for the statement
- Moderate recommendation for the statement
- Optional recommendation for the statement

Supplemental Table S1. Frequencies^a of *CYP2D6* alleles in major race/ethnic groups^b

| Allele | African | African American | Caucasian (European + North American) | Middle Eastern | East Asian | South/Central Asian | Americas | Oceanian |
|------------------------|----------------|-------------------------|--|-----------------------|-------------------|----------------------------|-----------------|-----------------|
| *1^c | 0.39 | 0.41 | 0.52 | 0.59 | 0.34 | 0.53 | 0.62 | 0.70 |
| *2^d | 0.20 | 0.12 | 0.27 | 0.24 | 0.12 | 0.31 | 0.24 | 0.012 |
| *3 | 0.0003 | 0.0034 | 0.013 | 0.0013 | 0.00 | 0.00 | 0.0052 | 0.00 |
| *4 | 0.033 | 0.06 | 0.18 | 0.076 | 0.0045 | 0.065 | 0.11 | 0.011 |
| *5 | 0.06 | 0.058 | 0.028 | 0.023 | 0.058 | 0.025 | 0.016 | 0.049 |
| *6 | 0.00 | 0.0027 | 0.0091 | 0.0096 | 0.0002 | 0.00 | 0.005 | 0.00 |
| *7 | 0.00 | 0.00 | 0.0012 | 0.00 | 0.00 | ND | 0.00 | 0.00 |
| *8 | 0.00 | 0.00 | 0.0003 | 0.00 | 0.00 | ND | 0.0015 | 0.00 |
| *9 | 0.0010 | 0.0054 | 0.02 | 0.00 | 0.0008 | 0.014 | 0.013 | 0.00 |
| *10^e | 0.067 | 0.043 | 0.028 | 0.035 | 0.42 | 0.19 | 0.034 | 0.016 |
| *14 | 0.0013 | 0.00 | 0.00 | 0.00 | 0.0092 | 0.00 | 0.0047 | 0.00 |
| *17^f | 0.19 | 0.18 | 0.0027 | 0.014 | 0.0002 | 0.0038 | 0.023 | 0.0005 |
| *36 | 0.00 | 0.0056 | 0.00 | 0.00 | 0.017 | ND | ND | 0.00 |
| *41^g | 0.10 | 0.10 | 0.092 | 0.22 | 0.022 | 0.10 | 0.057 | 0.00 |
| xN^h | 0.075 | 0.043 | 0.028 | 0.067 | 0.015 | 0.013 | 0.033 | 0.088 |

| | | | | | | | | |
|-------------------------|-------|--------|--------|-------|--------|--------|--------|------|
| <i>*1xNⁱ</i> | 0.014 | 0.0044 | 0.0077 | 0.038 | 0.0031 | 0.0050 | 0.0078 | 0.11 |
| <i>*2xNⁱ</i> | 0.015 | 0.016 | 0.013 | 0.036 | 0.0042 | 0.0050 | 0.023 | 0.00 |
| <i>*4xNⁱ</i> | 0.014 | 0.020 | 0.0028 | 0.00 | 0.00 | 0.00 | 0.0036 | 0.00 |

Abbreviations are as follows: ND = not determined

^aAverage frequencies are based on the actual number of subjects with each allele reported in multiple studies. For full details and references please see http://www.pharmgkb.org/download.action?filename=CYP2D6_Literature_Table_and_Legend.pdf.

^bWorldwide race/ethnic designations correspond to the Human Genome Diversity Project- Centre d'Etude du Polymorphisme Humain (HGDP-CEPH).^{55,56}

^cBecause *CYP2D6*1* is not genotyped directly, all alleles that are negative for a sequence variation are defaulted to a *CYP2D6*1* assignment. Likewise, sequence variations of alleles that are not tested also default to a *CYP2D6*1* assignment and hence contribute to the frequencies reported for this allele. The inferred frequency for *CYP2D6*1* is calculated as: 1 - (sum of variant allele frequencies).

^d*CYP2D6*2* is a 'default' assignment and, unless tested and discriminated for, *CYP2D6*8*, **11*, **17*, **35*, **41* along with other variants will default to a *CYP2D6*2* assignment. The frequencies shown here may therefore be over-estimated.

^e*CYP2D6*10* is a 'default' assignment and, unless tested and discriminated for, *CYP2D6*14* and **36* along with other variants will default to a *CYP2D6*10* assignment. The frequencies shown here may therefore be over-estimated.

^f*CYP2D6*17* is a 'default' assignment and, unless tested and discriminated for, *CYP2D6*40* and **58* will default to a *CYP2D6*17* assignment. The frequencies shown here may therefore be over-estimated.

^g*CYP2D6*41* has not consistently been determined by its defining SNP (2988G>A) across studies; some platforms still use the -1584C>G SNP to discriminate between *CYP2D6*2* and **41*. This may lead to an overestimation of the *CYP2D6*41* frequency, especially in Africans and their descendants.

^h*xN* denotes all gene duplications regardless of their nature. Alleles reported as *CYP2D6*2xN*, but not specifically discriminated from other duplications such as *CYP2D6*1xN* or **4xN* were tabulated as *xN*.

ⁱFrequencies calculated only from those studies which discriminated between gene duplications, that is studies that specified

duplications such as *CYP2D6*1xN*, **2xN*, or **4xN* were present. Because there may have been other duplications present and fewer studies had data for differentiated gene duplications, the sum of *CYP2D6*1xN*, **2xN*, and **4xN* is less than the sum shown for *xN*. *xN* may also contain other alleles with gene rearrangements that test positive in a duplication assay, but do not carry duplications of identical gene units.

Supplemental Table S2. Frequencies^a of *CYP2C19* alleles in major race/ethnic groups^b

| Allele | African | American | East Asian | European | Middle Eastern | Oceanian | South/Central Asian |
|-----------------------|---------|----------|------------|----------|----------------|----------|---------------------|
| *1^c | 0.68 | 0.69 | 0.60 | 0.63 | 0.87 | 0.24 | 0.62 |
| *2 | 0.15 | 0.12 | 0.29 | 0.15 | 0.12 | 0.61 | 0.35 |
| *3 | 0.0052 | 0.00028 | 0.089 | 0.0042 | 0.011 | 0.15 | 0.024 |
| *4 | 0.00093 | 0.0024 | 0.00049 | 0.0025 | ND | ND | 0.00 |
| *5 | ND | 0.00 | 0.00062 | 0.000073 | ND | ND | 0.00 |
| *6 | 0.00 | 0.00 | 0.00 | 0.00017 | ND | ND | 0.00 |
| *8 | 0.00 | 0.0012 | 0.00 | 0.0035 | ND | ND | ND |
| *17 | 0.16 | 0.18 | 0.027 | 0.21 | ND | ND | ND |

Abbreviations are as follows: ND = not determined

^aAverage frequencies are based on the actual number of subjects with each allele reported in multiple studies.

^bWorldwide race/ethnic designations correspond to the Human Genome Diversity Project- Centre d'Etude du Polymorphisme Humain (HGDP-CEPH)^{55,56}

^cBecause *CYP2C19**1 is not genotyped directly, all alleles that are negative for a sequence variation are defaulted to a *CYP2C19**1 assignment. Likewise, sequence variations of alleles that are not tested also default to a *CYP2C19**1 assignment and hence contribute to the frequencies reported for this allele. The inferred frequency for *CYP2C19**1 is calculated as: 1 - (sum of variant allele frequencies).

Supplemental Table S3. Commonly tested polymorphisms defining *CYP2D6* variant alleles and their effect on *CYP2D6* protein

| Allele ^a | Major Nucleotide Variation ^{b,c} | dbSNP Number ^d | Effect on <i>CYP2D6</i> Protein |
|---------------------|---|-------------------------------------|-------------------------------------|
| *1 ^e | - | - | - |
| *1xN | Gene duplication or multiplication | - | Increased protein expression |
| *2 ^f | 2850C>T 4180G>C ^g | rs16947 rs1135840 | R296C S486T |
| *2xN | Gene duplication or multiplication | - | Increased protein expression |
| *3 | 2549delA | rs35742686 | Frameshift |
| *4 | 100C>T, 1846G>A [4180G>C ^g] | rs1065852 rs3892097 rs1135840 | P34S, splicing defect [S486T] |
| *4xN | Gene duplication or multiplication | - | P34S, splicing defect |
| *5 | Gene deletion | N/A | Gene deletion |
| *6 | 1707delT | rs5030655 | Frameshift |
| *9 | 2615delAAG | rs5030656 | K281 deletion |
| *10 | 100C>T 4180G>C ^g | rs1065852 rs1135840 | P34S S486T |
| *17 | 1023C>T 2850C>T 4180G>C ^g | rs28371706 rs16947 rs1135840 | T107I R296C S486T |
| *41 | 2850C>T 2988G>A 4180G>C ^g | rs16947 rs28371725 rs1135840 | R296C Splicing defect S486T |

^aSee Human Cytochrome P450 Allele Nomenclature Committee website (<http://www.cypalleles.ki.se>) for comprehensive haplotype definitions of *CYP2D6* variant alleles and updated allele information.

^bAll coordinates refer to accession #M33388 as detailed at <http://www.cypalleles.ki.se/cyp2d6.htm>. All variants are annotated to the negative DNA strand.

^cSome alleles may carry multiple nucleotide variations. More specific details on the combinations of genetic variants present in each allele can be found at <http://www.cypalleles.ki.se> or <http://www.pharmgkb.org>. In addition, the specific genetic variants included in the genotyping assays that are used to distinguish each allele can be found in the assays' product insert.

^dRefSNP accession ID number (<http://www.ncbi.nlm.nih.gov/snp/>).

^eThe *CYP2D6**1 allele is characterized by the absence of any sequence variations. Consequently, this allele cannot be identified by a SNP; rather *CYP2D6**1 is assigned by default when no SNPs are detected during testing.

^fThe *CYP2D6**2 allele is characterized by two amino acid changes; both, however also occur in many other alleles. Therefore, if an allele carries these two SNPs exclusively, it is designated *CYP2D6**2. This is the only way to truly distinguish *CYP2D6**2 from other alleles (e.g., *CYP2D6**17 and *41).

^gThis SNP is present on many allelic variants including functional and non-functional variants. Specifically, it has been found on some *CYP2D6**4 subvariants. While some tests include this SNP, it cannot be utilized to identify an allelic variant with certainty.

Supplemental Table S4. Association between allelic variants^a and CYP2D6 enzyme activity

| Functional Status ^{8,25} | Activity Value ^{b,c} | Alleles |
|---|-------------------------------|---|
| Functional / normal activity / wild-type ^d | 1 | *1 ^e , *2, *27, *33, *35, *45 ^f , *46 ^f , *39, *48, *53 |
| Reduced function / decreased activity | 0.5 | *9, *10, *17, *29, *41, *49, *50, *54, *55, *59, *69, *72 |
| Non-functional / no activity | 0 | *3, *4, *5, *6, *7, *8, *11, *12, *13, *14, *15, *16, *18, *19, *20, *21, *31, *36, *38, *40, *42, *44, *47, *51, *56, *57, *62 |

^aSee <http://www.cypalleles.ki.se/cyp2d6.htm> for updates on *CYP2D6* allelic variants and nomenclature.

^bThere are additional allelic variants for which the activity value is unknown, therefore no *CYP2D6* activity score can be calculated. In such cases, the activity score may be estimated based on the second/known allele.

^cFor certain *CYP2D6* alleles *in vivo* data are lacking to unambiguously assign an activity value. For instance, the *CYP2D6**10 and *17 activity values may be substrate dependent, and for particular drugs the activity value could be closer to 1 (fully function) or 0 (non-functional). It should be noted that the *CYP2D6* activity score is a nominal scale. For example, an allele with an activity score of 0.5 does not necessarily have half the metabolic activity of an allele with an activity score of 1. The score of 0.5 indicates the allele has decreased metabolic activity compared to the wild-type allele when activity is measured towards probe substrates.

^dAn important caveat for all genotyping tests is that the decision to assign an allele a wild-type status is based upon a genotyping test that interrogates only the most common and already-proven sites of functional variation. It is always possible that a new, previously undiscovered (and therefore un-interrogated) site of variation may confer loss-of-function in an individual, and thus lead to the rare possibility of a non-functional allele being erroneously called as wild-type.

^e*CYP2D6**1 is defined as wild-type.

^fLimited data are available to determine the predicted activity value of *CYP2D6**45 and *46. Although an activity value of 1 (functional) is assigned to *CYP2D6**45 and *46 in this guideline, others may assign an activity value of 0.5 (reduced function).

Supplemental Table S5. Commonly tested polymorphisms defining *CYP2C19* variant alleles and their effect on *CYP2C19* protein

| Allele ^a | Major Nucleotide Variation ^b | dbSNP Number ^c | Effect on <i>CYP2C19</i> Protein |
|---------------------|---|---------------------------|----------------------------------|
| *1 | - | - | - |
| *2 | c.681G>A | rs4244285 | Splicing defect |
| *3 | c.636G>A | rs4986893 | W212X |
| *4 ^d | c.1A>G | rs28399504 | M1V |
| *5 | c.1297C>T | rs56337013 | R433W |
| *6 | c.395G>A | rs72552267 | R132Q |
| *7 | c.819+2T>A | rs72558186 | Splicing defect |
| *8 | c.358T>C | rs41291556 | W120R |
| *17 ^e | c.-806C>T | rs12248560 | Increased expression |

^aSee Human Cytochrome P450 Allele Nomenclature Committee (<http://www.cypalleles.ki.se>) for comprehensive haplotype definitions of *CYP2C19* variant alleles and updated allele information.

^bAll coordinates refer to GenBank *CYP2C19* mRNA sequence M61854.1 as detailed at <http://www.cypalleles.ki.se/cyp2c19.htm>. All variants are annotated to the positive DNA strand.

^cRefSNP accession ID number (<http://www.ncbi.nlm.nih.gov/snp/>).

^dThe *CYP2C19**4 loss-of-function allele has been identified in linkage disequilibrium with *17 (c.-806C>T) in certain ethnic subpopulations and this haplotype is designated *CYP2C19**4B.^{7,41}

^eThere is linkage disequilibrium between *CYP2C19**2 (c.681G) and *CYP2C19**17 (c.-806T). For instance, $D'=1.0$ and $r^2=0.064$ in CEU HapMap sample; $D'=1.0$ and $r^2=0.065$ in YRI HapMap sample; and $D'=1.0$ and $r^2=0.074$ in CHB HapMap sample.⁷

Supplemental Table S6. Association between allelic variants and CYP2C19 enzyme activity

| Functional Status | Alleles | References |
|---|----------------------------|-------------------|
| Functional / normal activity / wild-type ^a | *1 | 57 |
| Loss-of-function / no or decreased activity | *2, *3, *4, *5, *6, *7, *8 | 58-64 |
| Gain-of-function / increased activity | *17 | 65-67 |

^aAn important caveat for all genotyping tests is that the decision to assign an allele a wild-type status is based upon a genotyping test that interrogates only the most common and already-proven sites of functional variation. It is always possible that a new, previously undiscovered (and therefore un-interrogated) site of variation may confer loss-of-function in an individual, and thus lead to the rare possibility of a non-functional allele being erroneously called as wild-type.

Supplemental Table S7. Examples of *CYP2D6* genotypes with resulting activity scores and phenotype classification

| Allele 1 | Allele 2 | <i>CYP2D6</i> Diplotype | <i>CYP2D6</i> Activity Score ^a | Phenotype |
|-------------------|-------------------|-------------------------|---|-----------------|
| *1 | *1xN ^b | *1/*1xN | ≥3.0 | UM |
| *2x2 ^c | *41 | *2x2/*41 | 2.5 | UM |
| *1 | *2 | *1/*2 | 2.0 | EM |
| *1 | *17 | *1/*17 | 1.5 | EM |
| *2 | *3 | *2/*3 | 1.0 | EM |
| *1 | *4x2 ^d | *1/*4x2 | 1.0 | EM |
| *10 | *10 | *10/*10 ^e | 1.0 | EM ^e |
| *4 ^d | *10 | *4/*10 | 0.5 | IM |
| *5 | *6 | *5/*6 ^f | 0 | PM |

Abbreviations are as follows: EM = extensive metabolizer, IM = intermediate metabolizer, PM = poor metabolizer, UM = ultrarapid metabolizer. Extensive metabolizers with an activity score of 2.0 are expected to exhibit higher *CYP2D6* enzyme activity versus individuals with activity scores of 1.5 and 1.0, respectively.

^aThe *CYP2D6* activity score is calculated by summing the allele activity value for allele 1 and allele 2. The allele activity value is presented in Supplementary Table S4.

^b*1xN denotes that two or more copies of the *CYP2D6**1 allele are present. Because the activity value of *CYP2D6**1 is equal to 1, an activity value of 2 will be assigned to the *1xN allele in instances where a duplication is present (the activity value of each copy would be added together to equal 2). If three gene copies are present, the *1xN allele activity value would be equal to 3. Therefore, if *1xN is paired with a second functional allele, the activity score would be ≥3 with an exact value depending on the number of gene copies.

^c*2x2 denotes a duplication of a functional allele, therefore the allele activity value of *2x2 would be 2. In this example, the gene duplication is paired with *CYP2D6**41 (allele value = 0.5) resulting in a *CYP2D6* activity score of 2.5.

^dRegardless of the number of copies present, *CYP2D6**4 and *4xN are always considered non-functional alleles.

^eNote that some investigators may define patients with a *CYP2D6**10/*10 genotype as intermediate metabolizers

^fThe 1707delT variation will present as homozygous in a test due to the absence of a gene copy on the second allele. If no test is performed for the *CYP2D6**5 gene deletion, the genotype will be assigned as homozygous *CYP2D6* (*6/*6) which is technically inaccurate, but correctly predicts a PM phenotype. The same may occur in the presence of *CYP2D7/2D6* hybrid genes.

Supplemental Table S8. Predicted metabolizer phenotypes based on *CYP2D6* diplotypes

| Predicted Metabolizer Phenotype (Range Multi-Ethnic Frequency^a) | | | | | | | | | | | |
|---|-----------|-----------|-------------------------|-------------|-----------------------|-------------|-------------|-----------------|-----------------|-----------------|-----------------|
| Allele | *1 | *2 | *1xN or *2xN | *3 | *4 or *4xN | *5 | *6 | *9 | *10 | *17 | *41 |
| *1 | EM | EM | UM | EM | EM | EM | EM | EM | EM | EM | EM |
| *2 | | EM | UM | EM | EM | EM | EM | EM | EM | EM | EM |
| *1xN or *2xN | | | UM | EM or UM | EM or UM | EM or UM | EM or UM | UM | UM | UM | UM |
| *3 | | | | PM | PM | PM | PM | IM | IM | IM | IM |
| *4 | | | | | PM | PM | PM | IM | IM | IM | IM |
| *5 | | | | | | PM | PM | IM | IM | IM | IM |
| *6 | | | | | | | PM | IM | IM | IM | IM |
| *9 | | | | | | | | EM ^b | EM ^b | EM ^b | EM ^b |
| *10 | | | | | | | | | EM ^b | EM ^b | EM ^b |
| *17 | | | | | | | | | | EM ^b | EM ^b |
| *41 | | | | | | | | | | | EM ^b |

Abbreviations are as follows: EM = extensive metabolizer, IM = intermediate metabolizer, PM = poor metabolizer, UM = ultrarapid metabolizer

^aFrequencies of predicted metabolizer phenotypes can be estimated based on the frequencies provided in Supplementary Table S1.

^bNote that some investigators may define patients with these diplotypes as intermediate metabolizers.

Supplemental Table S9. Predicted metabolizer phenotypes based on *CYP2C19* diplotypes

| Predicted Metabolizer Phenotype (Range Multi-Ethnic Frequency ^a) | | | | | | | | | |
|--|----|----|----|----|----|----|----|----|------------------|
| Allele | *1 | *2 | *3 | *4 | *5 | *6 | *7 | *8 | *17 ^b |
| *1 | EM | IM | IM | IM | IM | IM | IM | IM | UM |
| *2 | | PM | PM | PM | PM | PM | PM | PM | IM ^c |
| *3 | | | PM | PM | PM | PM | PM | PM | IM ^c |
| *4 | | | | PM | PM | PM | PM | PM | IM ^c |
| *5 | | | | | PM | PM | PM | PM | IM ^c |
| *6 | | | | | | PM | PM | PM | IM ^c |
| *7 | | | | | | | PM | PM | IM ^c |
| *8 | | | | | | | | PM | IM ^c |
| *17 | | | | | | | | | UM |

Abbreviations are as follows: EM = extensive metabolizer, IM = intermediate metabolizer, PM = poor metabolizer, UM = ultrarapid metabolizer

^aFrequencies of predicted metabolizer phenotypes can be estimated based on the frequencies provided in Supplementary Table S2.

^bDue to conflicting data, the clinical importance of the *CYP2C19**17 allele is debated.^{7,65-67,69-74} For patients carrying the *CYP2C19**17 allele (e.g., patients with a *CYP2C19**17/*17, *CYP2C19**1/*17, or *CYP2C19**2/*17 diplotype), strong clinical data is lacking to suggest that these patients should receive different tricyclic doses than wild-type (*CYP2C19**1/*1) patients.

^cThe predicted phenotype is based on limited data; therefore, this is a provisional classification.^{68,69}

Supplemental Table S10. Tricyclic antidepressant metabolism by CYP2D6 and CYP2C19

| Parent drug | CYP2C19 metabolite^a | CYP2D6 metabolite^b | Therapeutic drug monitoring^c |
|------------------------------------|---|--------------------------------------|--|
| Amitriptyline^d | Nortriptyline^{e,d} | hydroxy-amitriptyline | amitriptyline + nortriptyline |
| Clomipramine^d | desmethyl-clomipramine^d | hydroxy-clomipramine | clomipramine + desmethyl-clomipramine |
| Desipramine^{e,d} | ----- | hydroxy-desipramine | desipramine |
| Doxepin^d | desmethyl-doxepin^d | hydroxy-doxepin | doxepin + desmethyl-doxepin |
| Imipramine^d | Desipramine^{e,d} | hydroxy-imipramine | imipramine + desmethyl-imipramine |
| Nortriptyline^{e,d} | ----- | hydroxy-nortriptyline | nortriptyline |
| Trimipramine^d | desmethyl-trimipramine^d | hydroxy-trimipramine | trimipramine + desmethyl-trimipramine |

^aThe pharmacologically active CYP2C19 metabolites are hydroxylated by CYP2D6 to less active compounds.

^bThe hydroxylated metabolites are glucuronidated, rendering the lipophilic drugs to water-soluble compounds that are renally eliminated.¹¹

^cThe parent drug and CYP2C19 metabolite are both pharmacologically active compounds. As a part of therapeutic drug monitoring the plasma concentrations of both are monitored.⁷⁵⁻⁷⁷

^dTricyclics are mixed serotonin and norepinephrine reuptake inhibitors. The tertiary amines amitriptyline, clomipramine, doxepin, imipramine, and trimipramine have a more pronounced serotonin reuptake inhibitor effect.⁷⁸⁻⁸⁰ The secondary amines desmethyl-clomipramine, desmethyl-doxepin, desmethyl-trimipramine, desipramine, and nortriptyline have a more pronounced norepinephrine reuptake inhibitor effect.⁷⁸⁻⁸⁰ *CYP2C19* or *CYP2D6* genetic variants may alter the ratio of tertiary to secondary amine plasma concentrations, thereby modulating antidepressant activity and side effects.⁷⁸

*Desipramine and nortriptyline are the CYP2C19 metabolites of imipramine and amitriptyline respectively. It should be noted that desipramine and nortriptyline are antidepressant drugs themselves.

Supplemental Table S11. Tricyclic antidepressant side effects^a

| Amitriptyline | CYP2C19 metabolite (Nortriptyline) | CYP2D6 metabolites (hydroxy-amitriptyline, hydroxy-nortriptyline) |
|--|--|---|
| Anticholinergic Affects Blurred vision Constipation Dizziness Urinary retention Xerostomia Cardiotoxicity Arrhythmias Heart Block Orthostatic hypotension Tachycardia Central nervous system toxicity Delirium Seizures Dementia Headache Sedation | Anticholinergic Affects Blurred vision Constipation Dizziness Urinary retention Xerostomia Cardiotoxicity Arrhythmias Heart Block Tachycardia | Cardiotoxicity Arrhythmias Heart Block Tachycardia |

^aThe more common and/or serious side effects associated with amitriptyline and its metabolites. The side effect profile of other tricyclics including clomipramine, desipramine, doxepin, imipramine and trimipramine is similar.⁷⁹

Anticholinergic side effects are common with the tricyclic antidepressants, which are due to the binding of these drugs to cholinergic receptors. The ranking of cholinergic receptor binding of the tricyclics is as follows: tertiary amines > secondary amines (desmethyl-metabolites) > hydroxy-metabolites.¹¹ Tricyclics also bind α -adrenergic, serotonin and histamine receptors resulting in orthostatic hypotension and sedation.⁸¹ Although patients with amitriptyline plus nortriptyline plasma concentrations within the recommended therapeutic range (80-200 ng/ml) may experience such effects, higher plasma concentrations of tertiary or secondary amines may place a patient at an increased risk of anticholinergic side effects along with orthostatic hypotension and sedation.⁷⁵ Amitriptyline plus nortriptyline plasma concentrations above the recommended therapeutic range are also associated with central nervous system and cardiac toxicity.⁸² Therefore, a CYP2D6 or CYP2C19 phenotype (e.g., a CYP2D6 or CYP2C19 poor metabolizer) that may result in increased plasma concentrations of tertiary or secondary amines could place a patient at an increased risk of adverse effects.

Tricyclic hydroxy-metabolites have lower binding affinities to muscarinic receptors, but have been associated with cardiotoxicity.⁸³⁻⁸⁶ In elderly depressed patients, plasma concentrations of hydroxy-nortriptyline metabolites were associated with increases in QRS duration and QTc intervals.⁸⁷ Stern *et al.* found that desipramine and hydroxy-desipramine plasma concentrations may predict prolongation of cardiac conduction in young adults.⁸⁸ Because CYP2D6 metabolizes tricyclics to hydroxy-metabolites, CYP2D6 ultrarapid

metabolizers may have elevated hydroxy-metabolite plasma concentrations resulting in an increased risk for cardiotoxicity.⁸⁹ It should be noted that therapeutic drug monitoring does not usually include measuring hydroxy-metabolite plasma concentrations; therefore, appropriate hydroxy-metabolite plasma concentrations have not been defined.

In addition to CYP P450 genetic polymorphisms, CYP P450 inhibitors can influence the plasma concentration of tricyclic antidepressants. There are multiple publications describing patients who have elevated tricyclic plasma concentrations when taking a tricyclic concomitantly with a CYP2D6 inhibitor.⁹⁰⁻⁹³ It has been suggested that the CYP2D6 activity score should be adjusted to 0 during treatment with a strong CYP2D6 inhibitor, and that patients should be treated similarly to CYP2D6 poor metabolizers.^{8,94} Patients taking strong inhibitors of CYP2D6, such as fluoxetine, in combination with a tricyclic might benefit from following the CYP2D6 poor metabolizer dosing recommendations in Table 2 located in the main document.

Although the occurrence of adverse events has been related in part to tricyclic steady-state concentrations, it should be noted that side effects may occur even when patients are within the recommended therapeutic range.^{11,82,95-100} Similarly, it has been hypothesized that tricyclic plasma concentrations above or below the recommended therapeutic range, or an imbalance between parent drug and metabolite concentrations, may lead to treatment failure, but conflicting data are present.^{11,81,82,95,101-108} Even though particular CYP2D6 or CYP2C19 phenotypes (e.g., ultrarapid or poor metabolizers) may place a patient at a higher risk of adverse effects or treatment failure, it does not necessarily mean extensive (normal) metabolizers are immune from side effects or treatment failure. Therefore, all patients should be monitored closely for side effects and treatment failure.

Supplemental Table S12. Evidence linking CYP2D6 and/or CYP2C19 phenotype or genotype with amitriptyline metabolism or response

| Type of experimental model (in vitro, in vivo preclinical, or clinical) | Major findings | References | Level of evidence ^a |
|--|--|---|--------------------------------|
| Evidence linking CYP2D6 and/or CYP2C19 phenotype/genotype with amitriptyline metabolism or response | | | |
| Clinical | Seven healthy volunteers were administered a single dose of 75 mg amitriptyline. Poor CYP2D6 metabolizers determined by debrisoquine phenotyping had higher amitriptyline plasma concentrations. | Balant-Gorgia <i>et al.</i> 1982 ¹⁰⁹ | High |
| Clinical | Twelve adult males were administered 50 mg amitriptyline to determine the role of CYP2C19 in demethylation of amitriptyline. The 6 CYP2C19 poor metabolizers had a significantly higher amitriptyline AUC than the 6 extensive metabolizers. The poor metabolizers had a significantly lower nortriptyline AUC than the extensive metabolizers. CYP2C19 polymorphisms had a significant effect on amitriptyline demethylation, but not on drug clearance or half-life. | Jiang <i>et al.</i> 2002 ¹¹⁰ | High |
| Clinical | In a Faroese patient group (n=23), no significant differences in the [(amitriptyline + nortriptyline plasma concentration)/dose] or median daily dose were found between extensive and poor CYP2D6 metabolizers. One poor metabolizer was found to exceed the recommended plasma concentration of amitriptyline + nortriptyline (130-325nM) with a concentration of 454nM. The median amitriptyline dose for all patients was 25 mg/day; therefore, one possible conclusion is that poor metabolizers taking lower doses of amitriptyline are not as likely to have plasma concentrations above the recommended therapeutic range. | Halling <i>et al.</i> 2008 ¹¹¹ | High |
| Clinical | The effect of <i>CYP2D6</i> *4 was studied in 1198 elderly Dutch patients. Antidepressant dose, antidepressant switching, and discontinuation of therapy were the primary end points. A total of 807 patients were taking a tricyclic antidepressant, and for these patients the risk of switching to another antidepressant was significantly higher in CYP2D6 poor metabolizers than extensive metabolizers (OR = 5.77; 95% CI 1.59, 21.03; p=0.01). There was also an increased risk of poor metabolizers discontinuing therapy when compared to extensive metabolizers, but the difference was not significant (OR = 1.45; 95% CI 0.91, 2.32; p=0.12). Although the starting dose of tricyclics was initially similar, the maintenance dose for poor metabolizers was lower than extensive metabolizers. The majority of patients were taking amitriptyline (n=551), though other tricyclics included clomipramine (n=79), nortriptyline (n=35), imipramine (n=29), and doxepin (n=4). | Bijl <i>et al.</i> 2008 ¹¹² | High |
| Clinical | Sixteen depressed patients were treated with 150 mg/day amitriptyline for 3 weeks. Four patients were determined to be poor CYP2D6 metabolizers based on debrisoquine phenotyping, and 1 patient was determined to be a poor CYP2C19 metabolizer based on mephenytoin metabolism. Three of the 5 poor metabolizers were found to have the highest amitriptyline + nortriptyline plasma concentrations on day 22. The other 2 poor metabolizers were analyzed on day 15 and found to have higher amitriptyline + | Baumann <i>et al.</i> 1986 ¹⁰⁴ | High |

| | | | |
|----------|---|---|----------|
| | nortriptyline plasma concentrations than the non-poor metabolizers. | | |
| Clinical | A total of 69 patients were investigated to determine the effect of <i>CYP2C19</i> genetic variants on the metabolic ratio (MR) of amitriptyline to nortriptyline. There was a significant difference in the logMR between patients with 2, 1 or no functional <i>CYP2C19</i> alleles. | van der Weide <i>et al.</i> 2005 ¹¹³ | High |
| Clinical | Fifty Caucasian patients receiving 75 mg twice daily amitriptyline were investigated to determine if <i>CYP2C19</i> and <i>CYP2D6</i> genetic variants affect outcomes. Patients with two functional <i>CYP2D6</i> alleles (<i>CYP2D6</i> *1, *2, *10, *41) were found to be at a low or medium low risk of side effects, and patients with at least one non-functional <i>CYP2D6</i> allele (<i>CYP2D6</i> *4) were found to be at a medium high to high risk of side effects. Additionally, particular combinations of <i>CYP2D6</i> and <i>CYP2C19</i> genetic variants had an effect upon side effect risk. | Steimer <i>et al.</i> 2005 ¹¹⁴ | High |
| Clinical | Prospective, blinded two-center study investigating the effect of <i>CYP2C19</i> and <i>CYP2D6</i> genetic variants on drug concentrations in 50 patients receiving amitriptyline 75 mg twice daily. <i>CYP2C19</i> heterozygotes (<i>CYP2C19</i> *1/*2) had higher amitriptyline and lower nortriptyline plasma concentrations than wild-types, but there was no change between groups in the total plasma concentrations for amitriptyline + nortriptyline. <i>CYP2D6</i> *41, *10 and *4 were associated with a 1.95, 2.67 and 3.83 fold increase respectively in the metabolic ratio of nortriptyline to hydroxy-nortriptyline. Based on the pharmacokinetic data, a semiquantitative gene dose of 1 was assigned to functional alleles, 0.5 for <i>CYP2D6</i> *10 and *41, and 0 for <i>CYP2D6</i> *4. This gene dose is comparable to the allele activity values in Supplementary Table S4. | Steimer <i>et al.</i> 2004 ¹¹⁵ | High |
| Clinical | A total of 678 Dutch patients were investigated to determine the effect of <i>CYP2D6</i> and <i>CYP2C19</i> , in particular <i>CYP2C19</i> *17, on drug metabolism. One hundred and fifty patients were taking amitriptyline. Patients carrying a <i>CYP2C19</i> *2 allele had significantly higher amitriptyline plasma concentrations, but <i>CYP2C19</i> genetic variants did not alter amitriptyline + nortriptyline plasma concentrations. <i>CYP2C19</i> *17 and <i>CYP2D6</i> non-functional alleles were significantly associated with patients having an elevated nortriptyline plasma concentration above the recommended range (50-150 ug/L) | de Vos <i>et al.</i> 2011 ⁶⁹ | High |
| Clinical | Fifty Japanese psychiatric patients were administered an average of 101.1 ± 53.7 mg/day of amitriptyline. Significantly higher plasma concentrations of amitriptyline were observed in patients with two variant <i>CYP2C19</i> alleles versus patients with no variant <i>CYP2C19</i> alleles. There was a trend towards a higher ratio of nortriptyline to its metabolite in patients with two variant <i>CYP2D6</i> alleles. However, no poor <i>CYP2D6</i> metabolizers as defined by this guideline were included in the patients carrying two variant <i>CYP2D6</i> alleles, which may explain why the results were not significant. | Shimoda <i>et al.</i> 2002 ¹⁰⁵ | High |
| Clinical | A case report of a patient determined to have a low debrisoquine metabolic ratio (indicates rapid <i>CYP2D6</i> metabolism) and a <i>CYP2D6</i> gene duplication. The patient had a low plasma concentration of | Bertilsson <i>et al.</i> 1993 ¹¹⁶ | Moderate |

| | | | |
|----------|---|--|----------|
| | amitriptyline + nortriptyline during amitriptyline therapy. Another study demonstrated a relationship between the number of functional <i>CYP2D6</i> genes and debrisoquine metabolism. | Bertilsson <i>et al.</i> 1985 ⁸⁹ Johansson <i>et al.</i> 1993 ¹¹⁷ | |
| Clinical | A total of 136 depressed patients treated with antidepressants were genotyped for <i>CYP2D6</i> , <i>CYP2C19</i> , and <i>CYP2C9</i> . A <i>CYP2D6</i> ultrarapid metabolizer was reported to have a 6% increased plasma concentration of amitriptyline + nortriptyline. A <i>CYP2C19</i> poor metabolizer had a 133% increased amitriptyline + nortriptyline plasma concentration. | Grasmader <i>et al.</i> 2004 ¹¹⁸ | Moderate |
| Clinical | Eleven healthy non-smokers were administered a single dose of 50 mg amitriptyline. Individuals with a higher debrisoquine to 4-OH-debrisoquin metabolic ratio (poor <i>CYP2D6</i> metabolism) had slower clearance of amitriptyline. | Mellstrom <i>et al.</i> 1986 ¹¹⁹ | Moderate |
| Clinical | A 55 year old Caucasian woman determined to be a <i>CYP2D6</i> poor metabolizer (<i>CYP2D6</i> *4/*4) demonstrated slow clearance of amitriptyline following an intentional overdose. | Smith <i>et al.</i> 2011 ¹²⁰ | Moderate |
| Clinical | A series of 202 postmortem toxicology cases were examined to investigate the role of <i>CYP2D6</i> and <i>CYP2C19</i> genetic variants in amitriptyline metabolism. The number of functional <i>CYP2D6</i> alleles was correlated to the plasma concentrations of nortriptyline and its hydroxy-metabolites, and the number of <i>CYP2C19</i> alleles was correlated to the plasma concentrations of amitriptyline and its metabolite nortriptyline. The presence of functional <i>CYP2D6</i> or <i>CYP2C19</i> alleles resulted in lower amitriptyline or nortriptyline plasma concentrations, respectively. | Koski <i>et al.</i> 2006 ¹²¹ | Moderate |
| Clinical | In 26 hospitalized depressed patients there was a positive correlation between nortriptyline plasma concentrations and the logMR (metabolic ratio) of dextromethorphan, and a positive correlation between amitriptyline plasma concentrations and the logMR of mephenytoin. | Breyer-Pfaff <i>et al.</i> 1992 ¹²² | Moderate |

^aThe grading system for evidence is explained in the section *level of evidence* located in the introduction.

Supplemental Table S13. Evidence linking *CYP2D6* phenotype or genotype with nortriptyline metabolism or response

| Type of experimental model (in vitro, in vivo preclinical, or clinical) | Major findings | References | Level of evidence ^a |
|--|----------------|------------|--------------------------------|
| Evidence linking <i>CYP2D6</i> phenotype/genotype with nortriptyline metabolism or response | | | |

| | | | |
|----------|--|--|------|
| Clinical | <i>CYP2D6</i> genotypes and nortriptyline plasma concentrations were obtained from 16 healthy Korean individuals. Subjects carrying at least one reduced function or non-functional <i>CYP2D6</i> allele had a longer nortriptyline half-life along with a larger maximum plasma concentration and AUC than subjects carrying only functional alleles or duplicated functional alleles. | Lee <i>et al.</i> 2006 ¹²³ | High |
| Clinical | Fifteen healthy Chinese volunteers were administered 25 mg nortriptyline and then analyzed for the effect of <i>CYP2D6*10</i> on plasma concentrations. <i>CYP2D6*10*10</i> subjects had a significantly higher half-life and AUC of nortriptyline and a significantly lower oral clearance when compared to <i>CYP2D6*1/*1</i> or <i>CYP*1/*10</i> individuals. No significant differences in nortriptyline half-life, AUC, or oral clearance were noted between <i>CYP2D6*1/*1</i> and <i>CYP2D6*1/*10</i> individuals. | Yue <i>et al.</i> 1998 ¹²⁴ | High |
| Clinical | Ten healthy Korean volunteers were given a single dose of 20 mg debrisoquine and 25 mg nortriptyline on separate occasions to study the influence of <i>CYP2D6*10</i> on disposition of these drugs. The AUC of 4-hydroxydebrisoquine was significantly lower in <i>CYP2D6*1/*10</i> individuals than <i>CYP2D6*1/*1</i> individuals. However no significant differences in nortriptyline plasma concentrations were noted between <i>CYP2D6*1/*10</i> and <i>CYP2D6*1/*1</i> individuals. | Dalen <i>et al.</i> 2003 ¹²⁵ | High |
| Clinical | Twenty-one healthy Caucasian subjects were given a single dose of 25 mg nortriptyline. Nortriptyline clearance was positively correlated with the number of functional <i>CYP2D6</i> genes present. | Dalen <i>et al.</i> 1998 ¹²⁶ Kvist <i>et al.</i> 2001 ¹²⁷ | High |
| Clinical | Twenty-three healthy Ghanaian (n=11) and Swedish (n=12) subjects were administered a single dose of 28.5 mg nortriptyline to investigate the correlation between nortriptyline and debrisoquine metabolism. Individuals with a higher metabolic ratio of debrisoquine (indicator of slow <i>CYP2D6</i> metabolism) had slower clearance of nortriptyline. | Woolhouse <i>et al.</i> 1984 ¹²⁸ | High |
| Clinical | Thirty-six geriatric patients taking concurrent medications were investigated to determine if nortriptyline plasma concentrations can be predicted by <i>CYP2D6</i> genotyping. Patients were divided into extensive metabolizers (<i>CYP2D6*1/*2</i> , <i>*1/*10B</i> , <i>*1/*1</i>) or impaired metabolizers (<i>CYP2D6*1/*4A</i> , <i>*2/*4A</i> , <i>*2/*10B</i> , <i>*1/*3</i> , <i>*2/*2</i> , <i>*10B/*5</i> , <i>*3/*4A</i> , <i>*4A/*4A</i>). Although the impaired metabolizers were taking a significantly lower nortriptyline dosage than extensive metabolizers, the impaired metabolizers had significantly higher nortriptyline plasma concentrations. | Murphy <i>et al.</i> 2001 ¹²⁹ | High |
| Clinical | Among 21 depressed patients taking 100-150 mg/day nortriptyline, a <i>CYP2D6</i> poor metabolizer was found to have the highest nortriptyline plasma concentration. There was not a significant difference in nortriptyline plasma concentrations between patients with two function <i>CYP2D6</i> genes or one functional and one non-functional <i>CYP2D6</i> gene. However, patients with one functional and one non-functional <i>CYP2D6</i> gene had significantly lower plasma concentrations of 10-OH-nortriptyline. | Dahl <i>et al.</i> 1996 ¹⁰⁷ Kvist <i>et al.</i> 2001 ¹²⁷ | High |
| Clinical | Side effects were analyzed in patients taking tricyclic antidepressants including nortriptyline along with amitriptyline, desipramine, clomipramine and imipramine. High dextromethorphan metabolic ratios (indicates poor <i>CYP2D6</i> metabolism) were associated with the reporting of adverse effects. Patients carrying a deficient <i>CYP2D6</i> gene had a significantly higher rate of reporting side effects. | Chen <i>et al.</i> 1996 ¹³⁰ | High |
| Clinical | The impact of <i>CYP2D6</i> genotypes on nortriptyline steady-state plasma concentrations were studied in | Morita <i>et al.</i> | High |

| | | | |
|----------|---|--|----------|
| | 41 Japanese psychiatric patients. The patients were divided into three groups as follows: patients carrying 0, 1, or 2 <i>CYP2D6</i> variant alleles. Nortriptyline plasma concentrations corrected for weight and dose were significantly higher in patients with 1 or 2 variant <i>CYP2D6</i> alleles when compared to patients with 0 variant alleles. | 2000 ¹³¹ | |
| Clinical | Twenty depressed patients were treated with nortriptyline for at least 3 weeks. The nortriptyline plasma concentrations correlated with debrisoquine metabolic ratio, with higher nortriptyline plasma concentrations observed in slower debrisoquine metabolizers (indicates slow <i>CYP2D6</i> metabolism). | Nordin <i>et al.</i> 1985 ¹³² Kvist <i>et al.</i> 2001 ¹²⁷ | High |
| Clinical | In 8 healthy volunteers the clearance of nortriptyline was positively related to debrisoquine metabolism. The slowest metabolizers of debrisoquine (indicates slow <i>CYP2D6</i> metabolism) had lower total clearance of nortriptyline. | Bertilsson <i>et al.</i> 1980 ¹³³ | Moderate |
| Clinical | The correlation of nortriptyline metabolism to debrisoquine metabolism was studied in 8 healthy subjects administered a single dose of 28.5 mg nortriptyline. Individuals with a higher metabolic ratio of debrisoquine (indicator of slow <i>CYP2D6</i> metabolism) had a higher nortriptyline AUC. | Mellstrom <i>et al.</i> 1981 ¹³⁴ | Moderate |
| Clinical | A 54 year old patient received 150 mg/day nortriptyline. The patient experienced side effects and had a higher plasma concentration than expected (470.6 ng/ml). A genotype test demonstrated that the patient had one deleted <i>CYP2D6</i> gene and one reduced function <i>CYP2D6</i> allele (<i>CYP2D6</i> *5/*10B). | Lee <i>et al.</i> 2004 ¹³⁵ | Moderate |
| Clinical | A patient determined to have a low debrisoquine metabolic ratio (indicates rapid <i>CYP2D6</i> metabolism) required 500 mg/day nortriptyline to achieve a therapeutic plasma concentration. The patient was found to have a <i>CYP2D6</i> gene duplication. Another study demonstrated a relationship between the number of functional <i>CYP2D6</i> genes and debrisoquine metabolism. | Bertilsson <i>et al.</i> 1993 ¹¹⁶ Bertilsson <i>et al.</i> 1985 ⁸⁹ Johansson <i>et al.</i> 1993 ¹¹⁷ | Moderate |
| Clinical | A 69 year old female was prescribed 25 mg nortriptyline administered three times daily. The patient experienced side effects and the nortriptyline plasma concentration was found to be 1300 nmol/L (usual range 200-600 nmol/L). The patient was phenotyped using the probe drug debrisoquine and found to be a <i>CYP2D6</i> poor metabolizer. | Bertilsson <i>et al.</i> 1981 ¹⁸ | Moderate |

^aThe grading system for evidence is explained in the section *level of evidence* located in the introduction.

Supplemental Table S14. Evidence linking *CYP2D6* and/or *CYP2C19* phenotype or genotype with clomipramine metabolism or response

| Type of experimental model (in vitro, in vivo preclinical, or clinical) | Major findings | References | Level of evidence ^a |
|---|--|-----------------------|--------------------------------|
| Evidence linking <i>CYP2D6</i> and/or <i>CYP2C19</i> phenotype/genotype with clomipramine metabolism or response | | | |
| Clinical | A total of 25 healthy subjects were phenotyped using the probe drugs sparteine and mephenytoin. Nine | Nielsen <i>et al.</i> | High |

| | | | |
|----------|---|--|----------|
| | subjects were poor CYP2D6 metabolizers, 5 subjects were poor CYP2C19 metabolizers, and 1 subject was both a poor CYP2D6 and CYP2C19 metabolizer. When compared to the extensive metabolizers, CYP2D6 or CYP2C19 poor metabolizers had a significantly lower clearance of clomipramine. | 1994 ¹³⁶ | |
| Clinical | A total of 678 Dutch patients were investigated to determine the effect of <i>CYP2D6</i> and <i>CYP2C19</i> , in particular <i>CYP2C19</i> *17, on drug metabolism. Two hundred and forty-four patients were taking clomipramine. Over all there was no clear trend between <i>CYP2C19</i> genetic variants and clomipramine or desmethyl-clomipramine plasma concentrations. However, <i>CYP2C19</i> *2/*2 patients had a significantly higher metabolic ratio of clomipramine to desmethyl-clomipramine than <i>CYP2C19</i> *1/*1 patients. <i>CYP2C19</i> *17/*17 patients had a significant association with subtherapeutic clomipramine plasma concentrations. No statistically significant effects were observed between <i>CYP2D6</i> genetic variants and clomipramine or desmethyl-clomipramine plasma concentrations. | de Vos <i>et al.</i> 2011 ⁶⁹ | High |
| Clinical | A total of 45 depressed Caucasian patients treated with clomipramine were genotyped for <i>CYP2D6</i> and phenotyped with dextromethorphan. There was a significant correlation between reported side effects and slower dextromethorphan metabolism (indicates slow CYP2D6 metabolism). There was a trend for higher reported side effects with patients carrying a non-functional <i>CYP2D6</i> gene. | Vandel <i>et al.</i> 2004 ¹³⁷ | High |
| Clinical | The effect of <i>CYP2D6</i> and <i>CYP2C19</i> genetic variants on the metabolism of clomipramine was studied in 51 Japanese psychiatric patients administered 10 to 250 mg/day clomipramine. There was a significant correlation with increasing clomipramine plasma concentrations and the number of variant <i>CYP2C19</i> alleles. No significant correlation was found between desmethyl-clomipramine plasma concentrations and the number of variant <i>CYP2D6</i> alleles. However, as defined by phenotype assignment in this CPIC guideline all patients in this study would have been CYP2D6 extensive metabolizers. | Yokono <i>et al.</i> 2001 ¹³⁸ | High |
| Clinical | One hundred and nine depressed patients enrolled on a clomipramine dose-effect study were phenotyped with sparteine (probe drug used to determine CYP2D6 metabolizer status). When compared to extensive metabolizers, poor metabolizers had a significantly higher desmethyl-clomipramine plasma concentration and a significantly higher clomipramine + desmethyl-clomipramine plasma concentration. | DUAG 1999 ¹³⁹ | High |
| Clinical | A total of 36 depressed patients were treated with 75 mg clomipramine twice daily. The patients were phenotyped using the probe drug sparteine (used to determine CYP2D6 metabolizer status). When compared to extensive metabolizers, CYP2D6 poor metabolizers had a significantly higher desmethyl-clomipramine plasma concentration. | Nielsen <i>et al.</i> 1992 ¹⁴⁰ | High |
| Clinical | A patient prescribed 150-225 mg/day clomipramine had low plasma concentrations of clomipramine and desmethyl-clomipramine. The patient was found to have a duplication of a functional <i>CYP2D6</i> gene. | Baumann <i>et al.</i> 1998 ¹⁴¹ | Moderate |
| Clinical | A psychiatric patient was initiated with 150 mg clomipramine daily, but no response to the drug was observed and the dose was increased to 225 mg/day. The plasma concentrations of the drug were much | Bertilsson <i>et al.</i> 1993 ¹¹⁶ | Moderate |

| | | | |
|----------|---|---|----------|
| | lower than expected and the dose was further increased to 300 mg/day. The patient was found to have a <i>CYP2D6</i> gene duplication. | Traskman <i>et al.</i> 1979 ¹⁴² | |
| Clinical | A 47-year-old male patient experienced multiple adverse drug reactions during therapy with clomipramine 225-300 mg/day and quetiapine 700 mg/day. Plasma concentrations were elevated (clomipramine + desmethyl-clomipramine 1228 ng/ml), and the patient was found to be a <i>CYP2D6</i> poor metabolizer (<i>CYP2D6</i> *4/*6). After reduction of the clomipramine dose to 75 mg/day and discontinuation of quetiapine, all adverse drug reactions resolved except for increased liver enzymes. The plasma concentration after dose reduction was 374 ng/ml clomipramine + desmethyl-clomipramine. | Stephan <i>et al.</i> 2006 ¹⁴³ | Moderate |
| Clinical | A patient taking 100 mg/day clomipramine was noted to have elevated plasma concentrations of the drug as follows: 148 ng/ml clomipramine and 450 ng/ml desmethyl-clomipramine. Although the dose was decreased, plasma concentrations continued to increase. The patient was found to be a <i>CYP2D6</i> poor metabolizer by debrisoquine phenotyping. | Balant-Gorgia <i>et al.</i> 1987 ¹⁴⁴ | Moderate |
| Clinical | A depressed patient was prescribed clomipramine 150 mg/day. After three weeks no clinical improvement was noted. The plasma concentration of clomipramine was 235 ng/ml and the desmethyl-clomipramine plasma concentration was 980 ng/ml. The patient was found to be a <i>CYP2D6</i> poor metabolizer by debrisoquine phenotyping. A dose of 50 mg/day lead to improvement of depressive symptoms and resulted in plasma concentrations of 60 ng/ml clomipramine and 165 ng/ml desmethyl-clomipramine. A second patient was prescribed clomipramine 225 mg/day. The patient had no improvement in depressive symptoms and experienced side effects. The plasma concentration of clomipramine was 160 ng/ml and the desmethyl-clomipramine plasma was 960 ng/ml. The patient was found to be a <i>CYP2D6</i> poor metabolizer by debrisoquine phenotyping. | Balant-Gorgia <i>et al.</i> 1989 ⁹³ | Moderate |

^aThe grading system for evidence is explained in the section *level of evidence* located in the introduction.

Supplemental Table S15. Evidence linking *CYP2D6* phenotype or genotype with desipramine metabolism or response

| Type of experimental model (in vitro, in vivo preclinical, or clinical) | Major findings | References | Level of evidence ^a |
|--|--|---|--------------------------------|
| Evidence linking <i>CYP2D6</i> phenotype/genotype with desipramine metabolism or response | | | |
| In Vitro and Clinical | A single oral dose of 25 mg desipramine was given to 18 healthy subjects phenotyped by the probe drug debrisoquine. Individuals with a higher debrisoquine metabolic ratio, indicative of <i>CYP2D6</i> poor metabolism, had a higher desipramine to hydroxy-desipramine ratio. There was a statistically significant correlation between debrisoquine metabolism and desipramine metabolism in human liver microsomes. Competitive inhibition studies demonstrated desipramine | Spina <i>et al.</i> 1984 ¹⁴⁵ | High |

| | | | |
|----------|---|---|------|
| | metabolism was dependent on CYP2D6 enzyme activity. | | |
| Clinical | The impact of CYP2D6 phenotype, determined by the probe drug sparteine, on desipramine hydroxylation was studied in patients administered 100 mg desipramine orally. Poor metabolizers had a significantly higher half-life and lower clearance of desipramine when compared to extensive metabolizers. | Brosen <i>et al.</i> 1986 ¹⁴⁶ | High |
| Clinical | The impact of CYP2D6 phenotype, determined by the probe drug sparteine, on first pass metabolism was studied in patients administered 50 mg desipramine intravenously. Poor metabolizers had a significantly higher half-life and lower clearance of desipramine when compared to extensive metabolizers. | Brosen <i>et al.</i> 1988 ¹⁴⁷ | High |
| Clinical | The effect of <i>CYP2D6</i> genetic variants on desipramine hydroxylation was studied in 223 Swedish subjects administered a single dose of 10 mg desipramine. Individuals were genotyped and phenotyped using the probe drugs debrisoquine and desipramine. The accuracy was 99% between predicted phenotype based on genotyping and the metabolic ratio of debrisoquine. There was a significant correlation between the metabolic ratios of debrisoquine and desipramine. | Dahl <i>et al.</i> 1992 ¹⁴⁸ | High |
| Clinical | Fourteen healthy volunteers were divided into rapid (n=8) or slow (n=6) metabolizer groups based on debrisoquine phenotyping. Desipramine AUC and half-life were significantly higher in poor metabolizers when compared to rapid metabolizers. The clearance of desipramine was also significantly lower in poor metabolizers. | Spina <i>et al.</i> 1987 ¹⁴⁹ | High |
| Clinical | The effect of CYP2D6 inhibition, using the moderate inhibitor cimetidine, on desipramine metabolism was studied in 9 subjects administered a single dose of 25 mg desipramine. The individuals were phenotyped using the probe drug debrisoquine and divided into two groups, rapid (n=5) and slow (n=4) metabolizers. Desipramine AUC and half-life were significantly greater in slow metabolizers than rapid metabolizers. The co-administration of 1200 mg cimetidine did not alter the pharmacokinetics of slow metabolizers, but the AUC and half-life of desipramine did increase in rapid metabolizers. | Steiner <i>et al.</i> 1987 ⁹² | High |
| Clinical | The impact of <i>CYP2D6</i> reduced function alleles on desipramine pharmacokinetics was studied in 16 subjects administered a single dose of 100 mg desipramine. The pharmacokinetic properties (half-life, C _{max} , AUC, and metabolic ratio) were similar between subjects carrying two functional alleles, a functional and reduced function allele, a functional and non-functional allele, or two reduced functional alleles. An individual with one reduced function and one non-functional allele had a higher AUC, half-life and metabolic ratio. | Furman <i>et al.</i> 2004 ¹⁵⁰ | High |
| Clinical | The impact of <i>CYP2D6</i> genetic variants on the metabolism of desipramine was studied in 18 Japanese psychiatric patients administered 50-250 mg/day desipramine. There was a significant correlation between the metabolic ratio of desipramine and the number of <i>CYP2D6</i> variant alleles, with a higher metabolic ratio (slower metabolism) observed in patients with two variant alleles. Patients with two variant alleles also had a significantly higher plasma concentration of desipramine. | Shimoda <i>et al.</i> 2000 ¹⁵¹ | High |
| Clinical | The relationship between CYP2D6 phenotype, desipramine plasma concentrations, and clinical | Spina <i>et al.</i> 1997 ¹⁰¹ | High |

| | | | |
|----------|--|--|----------|
| | response were studied in 31 patients treated with 100 mg/day desipramine for three weeks. The patients were phenotyped using the probe drug dextromethorphan. There was a significant correlation between desipramine plasma concentrations and dextromethorphan metabolic ratio, with slower dextromethorphan metabolizers (CYP2D6 poor metabolizers) having higher desipramine plasma concentrations. The two patients classified as CYP2D6 poor metabolizers experienced side effects and required a dose reduction to 50 mg/day. | | |
| Clinical | Among 35 depressed patients treated with 75 mg twice daily desipramine, 10 were selected for debrisoquine phenotyping and determination of desipramine plasma concentrations. There was a strong correlation between steady-state desipramine plasma concentrations and the debrisoquine metabolic ratio, with higher desipramine concentrations correlating with higher debrisoquine metabolic ratios (indicates slower metabolism). | Bertilsson <i>et al.</i> 1983 ¹⁵² | Moderate |
| Clinical | The effect of <i>CYP2D6</i> duplications was studied in 12 subjects (6 with duplications) after a single dose of 100 mg desipramine. Although not statistically significant, the individuals with <i>CYP2D6</i> duplications had a higher clearance (373 L/hr) of desipramine than the individuals with no duplications (196 L/hr). | Bergmann <i>et al.</i> 2001 ¹⁵³ | Moderate |
| Clinical | A 46 year old Caucasian male with chronic major depression was prescribed 250 mg/day desipramine. The patient experienced cardiotoxicity and was found to have a desipramine plasma concentration of 764 ng/ml (usual range 50-250). Based on debrisoquine phenotyping the patient was found to be a CYP2D6 poor metabolizer. | Bluhm <i>et al.</i> 1993 ¹⁵⁴ | Moderate |

^aThe grading system for evidence is explained in the section *level of evidence* located in the introduction.

Supplemental Table S16. Evidence linking CYP2D6 and/or CYP2C19 phenotype or genotype with doxepin metabolism or response

| Type of experimental model (in vitro, in vivo preclinical, or clinical) | Major findings | References | Level of evidence ^a |
|--|---|---|--------------------------------|
| Evidence linking CYP2D6 and/or CYP2C19 phenotype/genotype with doxepin metabolism or response | | | |
| In Vitro | CYP2C19 was demonstrated to substantially contribute to the metabolism of doxepin to desmethyl-doxepin. Inhibition experiments showed that the formation of desmethyl-doxepin was correlated to CYP2C19 enzymatic activity. | Hartter <i>et al.</i> 2002 ¹⁵⁵ | High |
| In Vitro | CYP2D6 was demonstrated to be the major enzyme of doxepin hydroxylation. Inhibition experiments showed that metabolism of doxepin, particularly the E-isomer, was correlated to CYP2D6 enzymatic activity. | Haritos <i>et al.</i> 2000 ¹⁵⁶ | High |
| Clinical | The contribution of CYP2D6 and CYP2C19 to the metabolism of doxepin was studied in 42 healthy volunteers administered a single dose of 75 mg doxepin. The volunteers were divided into poor, | Kirchheiner <i>et al.</i> | High |

| | | | |
|----------|---|---|----------|
| | intermediate or extensive metabolizers. There was a significant correlation between the number of <i>CYP2D6</i> non-functional alleles and oral clearance, plasma concentration, and half-life of doxepin and its desmethyl-metabolite. There was a significant correlation between the number of <i>CYP2C19</i> non-functional alleles and oral clearance of doxepin. | 2002 ¹⁵⁷ | |
| Clinical | The impact of <i>CYP2D6</i> ultrarapid metabolism on doxepin was studied in a total of 25 healthy volunteers administered a single dose of 75 mg doxepin. Ultrarapid <i>CYP2D6</i> metabolizers were found to have a significantly lower maximum plasma concentration (C _{max}) and AUC of the active compounds of the drug [(E,Z)-doxepin and (E,Z)-desmethyldoxepin] when compared to extensive metabolizers. Although the study was designed to determine the effects of <i>CYP2D6</i> ultrarapid metabolism on doxepin, poor metabolizers were noted to have a higher C _{max} and AUC of the active compounds when compared to extensive metabolizers. | Kirchheiner <i>et al.</i> 2005 ¹⁵⁸ | High |
| Clinical | A post mortem toxicology report showed a fatal doxepin poisoning. The blood concentration of doxepin was 2.4 mg/L, which is 16-80 times higher than therapeutic concentrations (0.03-0.15 mg/L). The individual was found to be a <i>CYP2D6</i> poor metabolizer (<i>CYP2D6</i> *3/*4). | Koski <i>et al.</i> 2007 ¹⁵⁹ | Moderate |
| Clinical | The debrisoquine metabolic ratio of four patients with elevated doxepin plasma concentrations was compared to 4 patients with normal doxepin plasma concentrations that were matched for sex, age and dose. No <i>CYP2D6</i> poor metabolizers were in the group with normal doxepin levels, but 50% of the patients with elevated doxepin levels were determined to be <i>CYP2D6</i> poor metabolizers. | Tacke <i>et al.</i> 1992 ¹⁶⁰ | Moderate |

^aThe grading system for evidence is explained in the section *level of evidence* located in the introduction.

Supplemental Table S17. Evidence linking *CYP2D6* and/or *CYP2C19* phenotype or genotype with imipramine metabolism or response

| Type of experimental model (in vitro, in vivo preclinical, or clinical) | Major findings | References | Level of evidence ^a |
|---|--|--|--------------------------------|
| Evidence linking <i>CYP2D6</i> and/or <i>CYP2C19</i> phenotype/genotype with imipramine metabolism or response | | | |
| In Vitro | The metabolism of imipramine was studied in human liver microsomes. The formation of 2-hydroxyimipramine was dependent on <i>CYP2D6</i> enzyme activity. | Brosen <i>et al.</i> 1991 ¹⁶¹ | High |
| Clinical | The relationship between <i>CYP2D6</i> phenotype, determined by sparteine phenotyping, and imipramine metabolism was investigated in families of 18 Danish poor metabolizers. The hydroxylation ratios (measurement of imipramine metabolism) were lower in poor metabolizers when compared to extensive metabolizers. | Madsen <i>et al.</i> 1996 ¹⁶² | High |
| Clinical | Imipramine metabolism was studied in 327 healthy subjects following a single dose of 25 mg imipramine. The subjects were phenotyped using the probe drugs sparteine and mephenytoin. Hydroxylation ratios were higher in the <i>CYP2D6</i> extensive metabolizers when compared to the poor | Madsen <i>et al.</i> 1995 ¹⁶³ | High |

| | | | |
|----------|---|--|------|
| | metabolizers. There was a significant correlation with mephenytoin metabolism and demethylation ratios. | | |
| Clinical | The impact of CYP2D6 phenotype, determined by the probe drug sparteine, on imipramine metabolism was studied in patients administered 100 mg imipramine orally. Poor metabolizers had significantly lower clearance of imipramine, but no statistically significant differences were observed in imipramine demethylation. The ratio of AUC desmethyl-imipramine to AUC imipramine was significantly higher in poor metabolizers. | Brosen <i>et al.</i> 1986 ¹⁴⁶ | High |
| Clinical | Imipramine metabolism was studied in 16 healthy subjects following a single dose of 25 mg imipramine. The subjects were phenotyped using the probe drugs metoprolol and mephenytoin and classified into three groups as follows: CYP2D6 extensive/CYP2C19 poor metabolizer, CYP2D6 poor/CYP2C19 extensive metabolizer, and CYP2D6/CYP2C19 extensive metabolizer. The clearance of imipramine was significantly lower in CYP2D6 extensive/CYP2C19 poor metabolizers when compared to CYP2D6/CYP2C19 extensive metabolizers. The AUC of desipramine was significantly greater in CYP2D6 poor/CYP2C19 extensive metabolizers than CYP2D6/CYP2C19 extensive metabolizers. | Koyama <i>et al.</i> 1994 ¹⁶⁴ | High |
| Clinical | The effect of <i>CYP2C19*17</i> on the metabolism of imipramine was studied in 178 depressed patients. The mean dose-corrected imipramine plasma concentration was significantly lower in <i>CYP2C19*17/*17</i> patients when compared to <i>CYP2C19*1/*1</i> patients. However, the mean dose-corrected imipramine + desipramine plasma concentrations were not significantly different between <i>CYP2C19</i> genotypes. | Schenk <i>et al.</i> 2010 ⁷⁴ | High |
| Clinical | The relationship between CYP2D6 phenotype, determined using the probe drug sparteine, and steady-state concentrations of imipramine was investigated in 35 patients treated with 100 mg/day imipramine. Poor metabolizers had a higher imipramine + desipramine plasma concentration than extensive metabolizers. | Brosen <i>et al.</i> 1986 ¹⁶⁵ | High |
| Clinical | The ability to predict drug dose using <i>CYP2D6</i> genotypes was investigated in 181 depressed patients treated with imipramine. Patient carrying only non-functional <i>CYP2D6</i> alleles had the lowest dose requirement (131 ± 109 mg/day) while patients with <i>CYP2D6</i> duplications had the highest dose requirement (509 ± 292 mg/day). There was a significant correlation between required imipramine dose and the number of variant <i>CYP2D6</i> alleles present. | Schenk <i>et al.</i> 2008 ¹⁶⁶ | High |
| Clinical | The effect of <i>CYP2C19</i> genetic variants on imipramine metabolism was studied in 10 depressed Japanese patients. Demethylation of imipramine was significantly lower in patients carrying <i>CYP2C19</i> variants, and plasma concentrations of imipramine + 2-hydroxyimipramine were significantly higher. | Morinobu <i>et al.</i> 1997 ¹⁶⁷ | High |
| Clinical | Imipramine steady-state concentrations were studied in 28 Japanese patients with major depression. Five of the patients were CYP2C19 poor metabolizers determined by mephenytoin phenotyping. All patients were CYP2D6 extensive metabolizers determined by metoprolol phenotyping. The CYP2C19 poor metabolizers had a 2.4 times greater imipramine plasma concentration and a 1.8 times greater imipramine + desipramine plasma concentration. | Koyama <i>et al.</i> 1996 ¹⁶⁸ | High |

| | | | |
|----------|---|--|----------|
| Clinical | Nineteen diabetic patients treated with imipramine for peripheral neuropathy were phenotyped with sparteine. Imipramine doses required to achieve therapeutic plasma concentrations were 20-25 mg/day in two poor metabolizers, 50 mg in extensive metabolizers, and 350 mg in a rapid metabolizer. In the extensive metabolizers, the concentration/dose ratio increased for imipramine and desipramine with increasing dose. | Sindrup <i>et al.</i> 1990 ¹⁶⁹ | High |
| Clinical | One hundred and six healthy subjects all CYP2D6 extensive metabolizers were phenotyped with mephenytoin and given a single dose of 25 mg imipramine. The desipramine/imipramine ratio and the 2-hydroxy desipramine/2-hydroxy imipramine ratios showed significant negative correlations with the mephenytoin S/R ratio. | Skjelbo <i>et al.</i> 1993 ¹⁷⁰ | High |
| Clinical | Twenty-two healthy subjects all CYP2D6 extensive metabolizers, except for 1 CYP2D6 poor metabolizer, received 100 mg imipramine (50 mg CYP2D6 poor metabolizer) and were phenotyped with mephenytoin. The 6 CYP2C19 poor metabolizers showed significant lower oral clearance, demethylation, and a reduced desipramine/imipramine ratio. | Skjelbo <i>et al.</i> 1991 ¹⁷¹ | High |
| Clinical | CYP2C19 was demonstrated to have a dominant role in demethylation of imipramine when compared to CYP1A2 or CYP3A4. | Madsen <i>et al.</i> 1997 ¹⁷² | Moderate |
| Clinical | A depressed patient was prescribed imipramine up to 150 mg/day. The patient did not improve and side effects were noted. The plasma concentration of imipramine was 125 ng/ml and the plasma concentration of desmethyl-imipramine was 1730 ng/ml. The patient was found to be a CYP2D6 poor metabolizer by debrisoquine phenotyping. Three other patients taking imipramine in combination with CYP2D6 inhibitors were found to have elevated plasma concentrations of imipramine and desmethyl-imipramine. | Balant-Gorgia <i>et al.</i> 1989 ⁹³ | Moderate |

^aThe grading system for evidence is explained in the section *level of evidence* located in the introduction.

Supplemental Table S18. Evidence linking CYP2D6 and/or CYP2C19 phenotype or genotype with trimipramine metabolism or response

| Type of experimental model (in vitro, in vivo preclinical, or clinical) | Major findings | References | Level of evidence ^a |
|---|---|---|--------------------------------|
| Evidence linking CYP2D6 and/or CYP2C19 phenotype/genotype with trimipramine metabolism or response | | | |
| Clinical | <p>The contribution of CYP2D6 and CYP2C19 to the metabolism of trimipramine was studied in 42 healthy volunteers administered a single dose of 75 mg trimipramine. The individuals were divided into poor, intermediate or extensive metabolizers. There was a significant decrease in clearance and increased half-life of trimipramine in intermediate and poor CYP2D6 metabolizers when compared to extensive metabolizers, and there was a significant increase in the AUC of both trimipramine and desmethyl-trimipramine observed in intermediate and poor CYP2D6 metabolizers.</p> <p>There was a significant decrease in clearance and increased half-life of trimipramine in intermediate and poor CYP2C19 metabolizers when compared to extensive metabolizers, and there was a significant increase in the AUC of trimipramine observed in intermediate and poor CYP2C19 metabolizers. CYP2C19 poor metabolizers had a significantly lower desmethyl-trimipramine AUC than extensive metabolizers.</p> | Kirchheiner <i>et al.</i> 2003 ¹⁷³ | High |
| Clinical | Trimipramine pharmacokinetics was studied in poor (n=5), extensive (n=7), and ultrarapid (n=3) metabolizers of CYP2D6. The oral bioavailability was significantly higher in poor metabolizers and the clearance significantly lower. In ultrarapid metabolizers, the oral bioavailability was significantly lower and the clearance significantly higher. | Kirchheiner <i>et al.</i> 2003 ¹⁷⁴ | High |
| Clinical | The pharmacokinetics and pharmacodynamics of trimipramine were studied in 2 healthy subjects following a single dose of 75 mg trimipramine on two separate occasions. Quinidine, an inhibitor of CYP2D6, was given with the second administration to mimic poor CYP2D6 metabolism. In the presence of quinidine, the half-life of trimipramine increased and the clearance of the drug decreased. EEG changes were noted as well when quinidine was administered in combination with trimipramine. | Eap <i>et al.</i> 1992 ⁹¹ | Moderate |
| Clinical | Twenty-seven schizophrenic patients received 300-400 mg/day trimipramine. One patient was found to be a CYP2D6 poor metabolizer based on dextromethorphan phenotyping and one patient was found to be a CYP2C19 poor metabolizer based on mephenytoin phenotyping. The CYP2D6 poor metabolizer had higher plasma concentrations of desmethyl-trimipramine and undetectable concentrations of hydroxylated metabolites. The CYP2C19 poor metabolizer had higher plasma concentrations of trimipramine and lower plasma concentrations of the desmethyl-metabolite. | Eap <i>et al.</i> 2000 ¹⁷⁵ | Moderate |

^aThe grading system for evidence is explained in the section *level of evidence* located in the introduction.

Supplemental Table S19. Dosing recommendations for amitriptyline based on both CYP2D6 and CYP2C19 phenotype^{a,b,c,d}

| Phenotype | CYP2D6 Ultrarapid metabolizer | CYP2D6 Extensive metabolizer | CYP2D6 Intermediate metabolizer | CYP2D6 Poor metabolizer |
|----------------------------------|---|---|---|--|
| CYP2C19 Ultrarapid metabolizer | Avoid tricyclic use. If a tricyclic is warranted utilize therapeutic drug monitoring to guide dose adjustment. | Consider alternative drug not metabolized by CYP2C19. If a tricyclic is warranted, utilize therapeutic drug monitoring to guide dose adjustments. | Consider alternative drug not metabolized by CYP2C19. If a tricyclic is warranted, utilize therapeutic drug monitoring to guide dose adjustments. | Avoid tricyclic use. If a tricyclic is warranted utilize therapeutic drug monitoring to guide dose adjustment. |
| CYP2C19 Extensive metabolizer | Avoid tricyclic use. If a tricyclic is warranted consider increasing the starting dose. ^a Utilize therapeutic drug monitoring to guide dose adjustments. | Initiate therapy with recommended starting dose. ^a | Consider 25% reduction of recommended starting dose. ^a Utilize therapeutic drug monitoring to guide dose adjustments. | Avoid tricyclic use. If a tricyclic is warranted consider 50% reduction of recommended starting dose. ^a Utilize therapeutic drug monitoring to guide dose adjustment. |
| CYP2C19 Intermediate metabolizer | Avoid tricyclic use. If a tricyclic is warranted utilize therapeutic drug monitoring to guide dose adjustments. | Initiate therapy with recommended starting dose. ^a | Consider 25% reduction of recommended starting dose. ^a Utilize therapeutic drug monitoring to guide dose adjustments. | Avoid tricyclic use. If a tricyclic is warranted consider 50% reduction of recommended starting dose. ^a Utilize therapeutic drug monitoring to guide dose adjustment. |
| CYP2C19 Poor metabolizer | Avoid tricyclic use. If a tricyclic is warranted utilize therapeutic drug monitoring to guide dose adjustments. | Consider 50% reduction of recommended starting dose. ^a Utilize therapeutic drug monitoring to guide dose adjustments. | Avoid tricyclic use. If a tricyclic is warranted utilize therapeutic drug monitoring to guide dose adjustments. | Avoid tricyclic use. If a tricyclic is warranted utilize therapeutic drug monitoring to guide dose adjustments. |

^aPatients may receive an initial low dose of tricyclics, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. ^bThe classification for all of the dosing recommendations in this table is optional. The rating scheme for the recommendation classification is described in the introduction of the Supplementary Data. ^cDosing recommendations only apply to higher initial doses of amitriptyline for treatment of conditions such as depression. See *other considerations* in the main document for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. ^dThe dosing recommendations are based on studies focusing on amitriptyline. Because tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply these guidelines to other tricyclic antidepressants including clomipramine, doxepin, imipramine and trimipramine. ^eTherapeutic drug monitoring of tricyclic antidepressants is well described in the literature.^{75-77,176,177} Because certain phenotype combinations are rare (e.g., CYP2C19 ultrarapid metabolizer also having CYP2D6 ultrarapid metabolism) sparse data are available to develop dosing recommendations. Therefore, we strongly recommend utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism.

Due to the increasing adoption of pharmacogenetic genotyping arrays, and the eventual adoption of exome sequencing, it will become more likely a clinician has genetic test results for multiple genes that affect a particular drug.^{10,35,178} Although dosing recommendations have been established for the gene-drug pair *VKORC1/CYP2C9*-warfarin⁵², in most instances there are insufficient data available to develop

other genes-drug pair guidelines. There has been interest in investigating the combined effects of *CYP2D6* and *CYP2C19* genetic variants on tricyclic dosing, but the frequency of certain phenotype combinations, such as a *CYP2D6* ultrarapid metabolizer also having *CYP2C19* poor metabolism, is expected to be low.^{114,136,157,164} Therefore, enrolling a sufficient number of patients on a clinical trial that represents all possible *CYP2D6* and *CYP2C19* phenotype combinations would be difficult. Steimer *et al.* demonstrated that particular *CYP2D6* and *CYP2C19* allele combinations have the potential to alter the pharmacokinetics of amitriptyline resulting in an increased risk of side effects.¹¹⁴ However, further studies are needed to develop moderate or strong dosing recommendations for tricyclics when considering combined *CYP2D6/CYP2C19* phenotypes. The optional dosing recommendations provided above were developed by assessment of the supporting data in Supplemental Table S12, and by combining the dosing recommendations from Tables 2 and 3 in the main document.

References

1. Whirl-Carrillo, M. *et al.* Pharmacogenomics knowledge for personalized medicine. *Clin Pharmacol Ther* **92**, 414-7 (2012).
2. Swen, J.J. *et al.* Pharmacogenetics: from bench to byte--an update of guidelines. *Clin Pharmacol Ther* **89**, 662-73 (2011).
3. Swen, J.J. *et al.* Pharmacogenetics: from bench to byte. *Clin Pharmacol Ther* **83**, 781-7 (2008).
4. Stingl, J.C., Brockmoller, J. & Viviani, R. Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function. *Mol Psychiatry* (2012).
5. Kirchheiner, J. *et al.* CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. *Acta Psychiatr Scand* **104**, 173-92 (2001).
6. Kirchheiner, J. *et al.* Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. *Mol Psychiatry* **9**, 442-73 (2004).
7. Scott, S.A. *et al.* Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. *Clin Pharmacol Ther* **90**, 328-32 (2011).
8. Crews, K.R. *et al.* Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. *Clin Pharmacol Ther* **91**, 321-6 (2012).
9. Robarge, J.D., Li, L., Desta, Z., Nguyen, A. & Flockhart, D.A. The star-allele nomenclature: retooling for translational genomics. *Clin Pharmacol Ther* **82**, 244-8 (2007).
10. Hicks, J.K. *et al.* A Clinician-Driven Automated System for Integration of Pharmacogenetic Interpretations Into an Electronic Medical Record. *Clin Pharmacol Ther* **92**, 563-566 (2012).
11. Rudorfer, M.V. & Potter, W.Z. Metabolism of tricyclic antidepressants. *Cell Mol Neurobiol* **19**, 373-409 (1999).
12. Tamminga, W.J. *et al.* Mephenytoin as a probe for CYP2C19 phenotyping: effect of sample storage, intra-individual reproducibility and occurrence of adverse events. *Br J Clin Pharmacol* **51**, 471-4 (2001).
13. Kirchheiner, J. CYP2D6 phenotype prediction from genotype: which system is the best? *Clin Pharmacol Ther* **83**, 225-7 (2008).
14. Basci, N.E. *et al.* Proguanil metabolism in relation to S-mephenytoin oxidation in a Turkish population. *Br J Clin Pharmacol* **42**, 771-3 (1996).
15. Wojtczak, A., Rychlik-Sych, M., Krochmalska-Ulacha, E. & Skretkiewicz, J. CYP2D6 phenotyping with dextromethorphan. *Pharmacol Rep* **59**, 734-8 (2007).
16. Chang, M., Dahl, M.L., Tybring, G., Gotharson, E. & Bertilsson, L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. *Pharmacogenetics* **5**, 358-63 (1995).
17. Kearns, G.L., Leeder, J.S. & Gaedigk, A. Impact of the CYP2C19*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect. *Drug Metab Dispos* **38**, 894-7 (2010).
18. Bertilsson, L., Mellstrom, B., Sjobqvist, F., Martenson, B. & Asberg, M. Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications. *Lancet* **1**, 560-1 (1981).
19. Tamminga, W.J. *et al.* The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers. *Eur J Clin Pharmacol* **57**, 717-22 (2001).
20. Kubota, T., Chiba, K. & Ishizaki, T. Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population. *Clin Pharmacol Ther* **60**, 661-6 (1996).

21. Niewinski, P. *et al.* CYP2D6 extensive, intermediate, and poor phenotypes and genotypes in a Polish population. *Eur J Clin Pharmacol* **58**, 533-5 (2002).
22. Brosen, K., de Morais, S.M., Meyer, U.A. & Goldstein, J.A. A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype. *Pharmacogenetics* **5**, 312-7 (1995).
23. McElroy, S. *et al.* CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting. *AAPS PharmSci* **2**, E33 (2000).
24. Chou, W.H. *et al.* Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. *Clin Chem* **49**, 542-51 (2003).
25. Gaedigk, A. *et al.* The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. *Clin Pharmacol Ther* **83**, 234-42 (2008).
26. Dahl, M.L., Johansson, I., Bertilsson, L., Ingelman-Sundberg, M. & Sjoqvist, F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. *J Pharmacol Exp Ther* **274**, 516-20 (1995).
27. Ramamoorthy, A. & Skaar, T.C. Gene copy number variations: it is important to determine which allele is affected. *Pharmacogenomics* **12**, 299-301 (2011).
28. Meijerman, I., Sanderson, L.M., Smits, P.H., Beijnen, J.H. & Schellens, J.H. Pharmacogenetic screening of the gene deletion and duplications of CYP2D6. *Drug Metab Rev* **39**, 45-60 (2007).
29. Kim, E.Y. *et al.* Robust CYP2D6 genotype assay including copy number variation using multiplex single-base extension for Asian populations. *Clin Chim Acta* **411**, 2043-8 (2010).
30. Lyon, E. *et al.* Laboratory testing of CYP2D6 alleles in relation to tamoxifen therapy. *Genet Med* **14**, 990-1000 (2012).
31. de Leon, J. *et al.* DNA microarray technology in the clinical environment: the AmpliChip CYP450 test for CYP2D6 and CYP2C19 genotyping. *CNS Spectr* **14**, 19-34 (2009).
32. Pratt, V.M. *et al.* Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: a GeT-RM and Association for Molecular Pathology collaborative project. *J Mol Diagn* **12**, 835-46 (2010).
33. Muller, D.J. *et al.* The AmpliChip((R)) CYP450 Test and Response to Treatment((in Schizophrenia and Obsessive Compulsive Disorder: A Pilot Study and Focus on Cases with Abnormal CYP2D6 Drug Metabolism. *Genet Test Mol Biomarkers* **16**, 897-903 (2012).
34. Fernandez, C.A. *et al.* Concordance of DMET Plus Genotyping Results With Those of Orthogonal Genotyping Methods. *Clin Pharmacol Ther* **92**, 360-365 (2012).
35. Pulley, J.M. *et al.* Operational Implementation of Prospective Genotyping for Personalized Medicine: The Design of the Vanderbilt PREDICT Project. *Clin Pharmacol Ther* **92**, 87-95 (2012).
36. Kawanishi, C., Lundgren, S., Agren, H. & Bertilsson, L. Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. *Eur J Clin Pharmacol* **59**, 803-7 (2004).
37. De la Vega, F.M., Lazaruk, K.D., Rhodes, M.D. & Wenz, M.H. Assessment of two flexible and compatible SNP genotyping platforms: TaqMan SNP Genotyping Assays and the SNPlex Genotyping System. *Mutat Res* **573**, 111-35 (2005).
38. Sibbing, D. *et al.* Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. *Circulation* **121**, 512-8 (2010).
39. Gurbel, P.A. *et al.* The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. *Am Heart J* **161**, 598-604 (2011).
40. Gurbel, P.A., Tantry, U.S., Shuldiner, A.R. & Kereiakes, D.J. Genotyping: one piece of the puzzle to personalize antiplatelet therapy. *J Am Coll Cardiol* **56**, 112-6 (2010).

41. Scott, S.A. *et al.* Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness. *Pharmacogenomics J* **12**, 297-305 (2012).
42. Roberts, J.D. *et al.* Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. *Lancet* **379**, 1705-11 (2012).
43. Lee, C.C., McMillin, G.A., Babic, N., Melis, R. & Yeo, K.T. Evaluation of a CYP2C19 genotype panel on the GenMark eSensor(R) platform and the comparison to the Autogenomics Infiniti and Luminex CYP2C19 panels. *Clin Chim Acta* **412**, 1133-7 (2011).
44. Mega, J.L. *et al.* Cytochrome p-450 polymorphisms and response to clopidogrel. *N Engl J Med* **360**, 354-62 (2009).
45. Collet, J.P. *et al.* Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. *Lancet* **373**, 309-17 (2009).
46. Simon, T. *et al.* Genetic determinants of response to clopidogrel and cardiovascular events. *N Engl J Med* **360**, 363-75 (2009).
47. Tobler, A.R. *et al.* The SNPlex genotyping system: a flexible and scalable platform for SNP genotyping. *J Biomol Tech* **16**, 398-406 (2005).
48. Valdes, R., Payne, D.A. & Linder, M.W. Laboratory analysis and application of pharmacogenetics to clinical practice. (*NACB, Washington, D.C., 2010*).
49. Wilke, R.A. *et al.* The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. *Clin Pharmacol Ther* **92**, 112-7 (2012).
50. Martin, M.A. *et al.* Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. *Clin Pharmacol Ther* **91**, 734-8 (2012).
51. Relling, M.V. *et al.* Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. *Clin Pharmacol Ther* **89**, 387-91 (2011).
52. Johnson, J.A. *et al.* Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. *Clin Pharmacol Ther* **90**, 625-9 (2011).
53. Relling, M.V. & Klein, T.E. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. *Clin Pharmacol Ther* **89**, 464-7 (2011).
54. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. December 1, 2009; 1-161. Page 2, Table #2. Vol. 2006.
55. Rosenberg, N.A. *et al.* Clines, clusters, and the effect of study design on the inference of human population structure. *PLoS Genet* **1**, e70 (2005).
56. Rosenberg, N.A. *et al.* Genetic structure of human populations. *Science* **298**, 2381-5 (2002).
57. Romkes, M., Faletto, M.B., Blaisdell, J.A., Raucy, J.L. & Goldstein, J.A. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. *Biochemistry* **30**, 3247-55 (1991).
58. De Morais, S.M. *et al.* Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. *Mol Pharmacol* **46**, 594-8 (1994).
59. de Morais, S.M. *et al.* The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. *J Biol Chem* **269**, 15419-22 (1994).
60. Xiao, Z.S. *et al.* Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. *J Pharmacol Exp Ther* **281**, 604-9 (1997).
61. Ferguson, R.J. *et al.* A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. *J Pharmacol Exp Ther* **284**, 356-61 (1998).

62. Ibeanu, G.C. *et al.* A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. *J Pharmacol Exp Ther* **290**, 635-40 (1999).
63. Ibeanu, G.C. *et al.* An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. *Pharmacogenetics* **8**, 129-35 (1998).
64. Ibeanu, G.C. *et al.* Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. *J Pharmacol Exp Ther* **286**, 1490-5 (1998).
65. Sim, S.C. *et al.* A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. *Clin Pharmacol Ther* **79**, 103-13 (2006).
66. Rudberg, I., Mohebi, B., Hermann, M., Refsum, H. & Molden, E. Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. *Clin Pharmacol Ther* **83**, 322-7 (2008).
67. Li-Wan-Po, A., Girard, T., Farndon, P., Cooley, C. & Lithgow, J. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. *Br J Clin Pharmacol* **69**, 222-30 (2010).
68. Sibbing, D. *et al.* Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. *J Thromb Haemost* **8**, 1685-93 (2010).
69. de Vos, A., van der Weide, J. & Looovers, H.M. Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients. *Pharmacogenomics J* **11**, 359-67 (2011).
70. Gawronska-Szklarz, B. *et al.* CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers. *Eur J Clin Pharmacol* **68**, 1267-74 (2012).
71. Ohlsson Rosenborg, S. *et al.* Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects. *Eur J Clin Pharmacol* **64**, 1175-9 (2008).
72. Baldwin, R.M. *et al.* Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. *Br J Clin Pharmacol* **65**, 767-74 (2008).
73. Harmsze, A.M. *et al.* The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. *Pharmacogenet Genomics* **22**, 169-75 (2012).
74. Schenk, P.W. *et al.* The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients. *Pharmacogenomics J* **10**, 219-25 (2010).
75. Hiemke, C. *et al.* AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. *Pharmacopsychiatry* **44**, 195-235 (2011).
76. Gram, L.F. Plasma level monitoring of tricyclic antidepressant therapy. *Clin Pharmacokinet* **2**, 237-51 (1977).
77. Sjoqvist, F., Bertilsson, L. & Asberg, M. Monitoring tricyclic antidepressants. *Ther Drug Monit* **2**, 85-93 (1980).
78. Shimoda, K. *et al.* Pronounced differences in the disposition of clomipramine between Japanese and Swedish patients. *J Clin Psychopharmacol* **19**, 393-400 (1999).
79. Teter, C.J., Kando, J.C., Wells, B.G. & Hayes, P.E. Depressive Disorders. in *Pharmacotherapy: A Pathophysiologic Approach* (eds DiPiro, J.T. *et al.*) (McGraw-Hill Companies, 2008).
80. Gillman, P.K. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. *Br J Pharmacol* **151**, 737-48 (2007).
81. Preskorn, S.H., Dorey, R.C. & Jerkovich, G.S. Therapeutic drug monitoring of tricyclic antidepressants. *Clin Chem* **34**, 822-8 (1988).
82. Ulrich, S. & Lauter, J. Comprehensive survey of the relationship between serum concentration and therapeutic effect of amitriptyline in depression. *Clin Pharmacokinet* **41**, 853-76 (2002).

83. Nordin, C., Bertilsson, L. & Siwers, B. CSF and plasma levels of nortriptyline and its 10-hydroxy metabolite. *Br J Clin Pharmacol* **20**, 411-3 (1985).
84. Nordin, C., Collste, P., Otani, K. & Scheinin, M. Effects of nortriptyline and its 10-hydroxy metabolite on plasma noradrenaline (NA) concentrations, heart rate and blood pressure during intravenous NA infusion. *Methods Find Exp Clin Pharmacol* **9**, 691-6 (1987).
85. Pollock, B.G., Everett, G. & Perel, J.M. Comparative cardiotoxicity of nortriptyline and its isomeric 10-hydroxymetabolites. *Neuropsychopharmacology* **6**, 1-10 (1992).
86. Bertilsson, L. *et al.* Disposition of single oral doses of E-10-hydroxynortriptyline in healthy subjects, with some observations on pharmacodynamic effects. *Clin Pharmacol Ther* **40**, 261-7 (1986).
87. Schneider, L.S., Cooper, T.B., Severson, J.A., Zemplyni, T. & Sloane, R.B. Electrocardiographic changes with nortriptyline and 10-hydroxynortriptyline in elderly depressed outpatients. *J Clin Psychopharmacol* **8**, 402-8 (1988).
88. Stern, S.L. *et al.* 2-Hydroxydesipramine and desipramine plasma levels and electrocardiographic effects in depressed younger adults. *J Clin Psychopharmacol* **11**, 93-8 (1991).
89. Bertilsson, L., Aberg-Wistedt, A., Gustafsson, L.L. & Nordin, C. Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. *Ther Drug Monit* **7**, 478-80 (1985).
90. Pawar, P.S. & Woo, D.A. Extrapyrimal symptoms with concomitant use of amitriptyline and amiodarone in an elderly patient. *Am J Geriatr Pharmacother* **8**, 595-8 (2010).
91. Eap, C.B. *et al.* Influence of quinidine on the pharmacokinetics of trimipramine and on its effect on the waking EEG of healthy volunteers. A pilot study on two subjects. *Neuropsychobiology* **25**, 214-20 (1992).
92. Steiner, E. & Spina, E. Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators. *Clin Pharmacol Ther* **42**, 278-82 (1987).
93. Balant-Gorgia, A.E., Balant, L.P. & Garrone, G. High blood concentrations of imipramine or clomipramine and therapeutic failure: a case report study using drug monitoring data. *Ther Drug Monit* **11**, 415-20 (1989).
94. Borges, S. *et al.* Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. *J Clin Pharmacol* **50**, 450-8 (2010).
95. Asberg, M., Cronholm, B., Sjoqvist, F. & Tuck, D. Relationship between plasma level and therapeutic effect of nortriptyline. *Br Med J* **3**, 331-4 (1971).
96. Hammer, W. & Sjoqvist, F. Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. *Life Sci* **6**, 1895-903 (1967).
97. Rudorfer, M.V. & Potter, W.Z. Pharmacokinetics of antidepressants. in *Psychopharmacology: The Third Generation of Progress* (ed. Meltzer, H.Y.) 1353-1363 (Raven Press, New York, 1987).
98. Preskorn, S.H. & Irwin, H.A. Toxicity of tricyclic antidepressants--kinetics, mechanism, intervention: a review. *J Clin Psychiatry* **43**, 151-6 (1982).
99. Rudorfer, M.V., Manji, H.K. & Potter, W.Z. Comparative tolerability profiles of the newer versus older antidepressants. *Drug Saf* **10**, 18-46 (1994).
100. Potter, W.Z., Rudorfer, M.V. & Manji, H. The pharmacologic treatment of depression. *N Engl J Med* **325**, 633-42 (1991).
101. Spina, E. *et al.* Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. *Eur J Clin Pharmacol* **51**, 395-8 (1997).
102. Nelson, J.C., Jatlow, P., Quinlan, D.M. & Bowers, M.B., Jr. Desipramine plasma concentration and antidepressant response. *Arch Gen Psychiatry* **39**, 1419-22 (1982).

103. Amsterdam, J.D., Brunswick, D.J., Potter, L., Winokur, A. & Rickels, K. Desipramine and 2-hydroxydesipramine plasma levels in endogenous depressed patients. Lack of correlation with therapeutic response. *Arch Gen Psychiatry* **42**, 361-4 (1985).
104. Baumann, P. *et al.* Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. *Int Clin Psychopharmacol* **1**, 102-12 (1986).
105. Shimoda, K. *et al.* The impact of CYP2C19 and CYP2D6 genotypes on metabolism of amitriptyline in Japanese psychiatric patients. *J Clin Psychopharmacol* **22**, 371-8 (2002).
106. Shimoda, K. *et al.* Significance of monitoring plasma levels of amitriptyline, and its hydroxylated and desmethylated metabolites in prediction of the clinical outcome of depressive state. *Psychiatry Clin Neurosci* **51**, 35-41 (1997).
107. Dahl, M.L., Bertilsson, L. & Nordin, C. Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype. *Psychopharmacology (Berl)* **123**, 315-9 (1996).
108. Nordin, C., Bertilsson, L. & Siwers, B. Clinical and biochemical effects during treatment of depression with nortriptyline: the role of 10-hydroxynortriptyline. *Clin Pharmacol Ther* **42**, 10-9 (1987).
109. Balant-Gorgia, A.E. *et al.* Role of oxidation polymorphism on blood and urine concentrations of amitriptyline and its metabolites in man. *Arch Psychiatr Nervenkr* **232**, 215-22 (1982).
110. Jiang, Z.P. *et al.* The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects. *Eur J Clin Pharmacol* **58**, 109-13 (2002).
111. Halling, J., Weihe, P. & Brosen, K. The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population. *Br J Clin Pharmacol* **65**, 134-8 (2008).
112. Bijl, M.J. *et al.* Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants. *Br J Clin Pharmacol* **65**, 558-64 (2008).
113. van der Weide, J., van Baalen-Benedek, E.H. & Kootstra-Ros, J.E. Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype. *Ther Drug Monit* **27**, 478-83 (2005).
114. Steimer, W. *et al.* Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. *Clin Chem* **51**, 376-85 (2005).
115. Steimer, W. *et al.* Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. *Clin Chem* **50**, 1623-33 (2004).
116. Bertilsson, L. *et al.* Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. *Lancet* **341**, 63 (1993).
117. Johansson, I. *et al.* Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. *Proc Natl Acad Sci U S A* **90**, 11825-9 (1993).
118. Grasmader, K. *et al.* Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. *Eur J Clin Pharmacol* **60**, 329-36 (2004).
119. Mellstrom, B., Sawe, J., Bertilsson, L. & Sjoqvist, F. Amitriptyline metabolism: association with debrisoquin hydroxylation in nonsmokers. *Clin Pharmacol Ther* **39**, 369-71 (1986).
120. Smith, J.C. & Curry, S.C. Prolonged toxicity after amitriptyline overdose in a patient deficient in CYP2D6 activity. *J Med Toxicol* **7**, 220-3 (2011).
121. Koski, A. *et al.* CYP2D6 and CYP2C19 genotypes and amitriptyline metabolite ratios in a series of medicolegal autopsies. *Forensic Sci Int* **158**, 177-83 (2006).

122. Breyer-Pfaff, U. *et al.* Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes. *Clin Pharmacol Ther* **52**, 350-8 (1992).
123. Lee, S.Y. *et al.* Sequence-based CYP2D6 genotyping in the Korean population. *Ther Drug Monit* **28**, 382-7 (2006).
124. Yue, Q.Y. *et al.* Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes. *Clin Pharmacol Ther* **64**, 384-90 (1998).
125. Dalen, P. *et al.* Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians. *Br J Clin Pharmacol* **55**, 630-4 (2003).
126. Dalen, P., Dahl, M.L., Bernal Ruiz, M.L., Nordin, J. & Bertilsson, L. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. *Clin Pharmacol Ther* **63**, 444-52 (1998).
127. Kvist, E.E. *et al.* Quantitative pharmacogenetics of nortriptyline: a novel approach. *Clin Pharmacokinet* **40**, 869-77 (2001).
128. Woolhouse, N.M. *et al.* Nortriptyline and debrisoquine hydroxylations in Ghanaian and Swedish subjects. *Clin Pharmacol Ther* **36**, 374-8 (1984).
129. Murphy, G.M., Jr. *et al.* CYP2D6 genotyping with oligonucleotide microarrays and nortriptyline concentrations in geriatric depression. *Neuropsychopharmacology* **25**, 737-43 (2001).
130. Chen, S. *et al.* The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. *Clin Pharmacol Ther* **60**, 522-34 (1996).
131. Morita, S. *et al.* Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: impact of CYP2D6 genotype on the hydroxylation of nortriptyline. *J Clin Psychopharmacol* **20**, 141-9 (2000).
132. Nordin, C., Siwers, B., Benitez, J. & Bertilsson, L. Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients--relationship to the debrisoquine hydroxylation metabolic ratio. *Br J Clin Pharmacol* **19**, 832-5 (1985).
133. Bertilsson, L. *et al.* Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. *Life Sci* **27**, 1673-7 (1980).
134. Mellstrom, B., Bertilsson, L., Sawe, J., Schulz, H.U. & Sjoqvist, F. E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation. *Clin Pharmacol Ther* **30**, 189-93 (1981).
135. Lee, S.Y., Ki, C.S., Hong, K.S. & Kim, J.W. A case report of a poor metabolizer of CYP2D6 presented with unusual responses to nortriptyline medication. *J Korean Med Sci* **19**, 750-2 (2004).
136. Nielsen, K.K., Brosen, K., Hansen, M.G. & Gram, L.F. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms. *Clin Pharmacol Ther* **55**, 518-27 (1994).
137. Vandel, P. *et al.* Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients. *Hum Psychopharmacol* **19**, 293-8 (2004).
138. Yokono, A. *et al.* The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients. *J Clin Psychopharmacol* **21**, 549-55 (2001).
139. Clomipramine dose-effect study in patients with depression: clinical end points and pharmacokinetics. Danish University Antidepressant Group (DUAG). *Clin Pharmacol Ther* **66**, 152-65 (1999).
140. Nielsen, K.K., Brosen, K. & Gram, L.F. Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism. Danish University Antidepressant Group. *Eur J Clin Pharmacol* **43**, 405-11 (1992).

141. Baumann, P., Broly, F., Kosel, M. & Eap, C.B. Ultrarapid metabolism of clomipramine in a therapy-resistant depressive patient, as confirmed by CYP2 D6 genotyping. *Pharmacopsychiatry* **31**, 72 (1998).
142. Traskman, L. *et al.* Plasma levels of chlorimipramine and its demethyl metabolite during treatment of depression. *Clin Pharmacol Ther* **26**, 600-10 (1979).
143. Stephan, P.L., Jaquenoud Sirot, E., Mueller, B., Eap, C.B. & Baumann, P. Adverse drug reactions following nonresponse in a depressed patient with CYP2D6 deficiency and low CYP 3A4/5 activity. *Pharmacopsychiatry* **39**, 150-2 (2006).
144. Balant-Gorgia, A.E., Balant, L. & Zysset, T. High plasma concentrations of desmethylclomipramine after chronic administration of clomipramine to a poor metabolizer. *Eur J Clin Pharmacol* **32**, 101-2 (1987).
145. Spina, E. *et al.* Phenotypic consistency in hydroxylation of desmethyylimipramine and debrisoquine in healthy subjects and in human liver microsomes. *Clin Pharmacol Ther* **36**, 677-82 (1984).
146. Brosen, K., Otton, S.V. & Gram, L.F. Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype. *Clin Pharmacol Ther* **40**, 543-9 (1986).
147. Brosen, K. & Gram, L.F. First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype. *Clin Pharmacol Ther* **43**, 400-6 (1988).
148. Dahl, M.L., Johansson, I., Palmertz, M.P., Ingelman-Sundberg, M. & Sjoqvist, F. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. *Clin Pharmacol Ther* **51**, 12-7 (1992).
149. Spina, E., Steiner, E., Ericsson, O. & Sjoqvist, F. Hydroxylation of desmethyylimipramine: dependence on the debrisoquin hydroxylation phenotype. *Clin Pharmacol Ther* **41**, 314-9 (1987).
150. Furman, K.D. *et al.* Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics. *Pharmacogenetics* **14**, 279-84 (2004).
151. Shimoda, K. *et al.* Metabolism of desipramine in Japanese psychiatric patients: the impact of CYP2D6 genotype on the hydroxylation of desipramine. *Pharmacol Toxicol* **86**, 245-9 (2000).
152. Bertilsson, L. & Aberg-Wistedt, A. The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine. *Br J Clin Pharmacol* **15**, 388-90 (1983).
153. Bergmann, T.K., Bathum, L. & Brosen, K. Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6. *Eur J Clin Pharmacol* **57**, 123-7 (2001).
154. Bluhm, R.E., Wilkinson, G.R., Shelton, R. & Branch, R.A. Genetically determined drug-metabolizing activity and desipramine-associated cardiotoxicity: a case report. *Clin Pharmacol Ther* **53**, 89-95 (1993).
155. Hartter, S., Tybring, G., Friedberg, T., Weigmann, H. & Hiemke, C. The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. *Pharm Res* **19**, 1034-7 (2002).
156. Haritos, V.S., Ghabrial, H., Ahokas, J.T. & Ching, M.S. Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin. *Pharmacogenetics* **10**, 591-603 (2000).
157. Kirchheiner, J., Meineke, I., Muller, G., Roots, I. & Brockmoller, J. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. *Pharmacogenetics* **12**, 571-80 (2002).
158. Kirchheiner, J. *et al.* Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets. *Pharmacogenet Genomics* **15**, 579-87 (2005).
159. Koski, A., Ojanpera, I., Sistonen, J., Vuori, E. & Sajantila, A. A fatal doxepin poisoning associated with a defective CYP2D6 genotype. *Am J Forensic Med Pathol* **28**, 259-61 (2007).
160. Tacke, U. *et al.* Debrisoquine hydroxylation phenotypes of patients with high versus low to normal serum antidepressant concentrations. *J Clin Psychopharmacol* **12**, 262-7 (1992).

161. Brosen, K., Zeugin, T. & Meyer, U.A. Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine. *Clin Pharmacol Ther* **49**, 609-17 (1991).
162. Madsen, H., Hansen, T.S. & Brosen, K. Imipramine metabolism in relation to the sparteine oxidation polymorphism--a family study. *Pharmacogenetics* **6**, 513-9 (1996).
163. Madsen, H., Nielsen, K.K. & Brosen, K. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study. *Br J Clin Pharmacol* **39**, 433-9 (1995).
164. Koyama, E. *et al.* Metabolic disposition of imipramine in oriental subjects: relation to metoprolol alpha-hydroxylation and S-mephenytoin 4'-hydroxylation phenotypes. *J Pharmacol Exp Ther* **271**, 860-7 (1994).
165. Brosen, K. *et al.* Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism. *Eur J Clin Pharmacol* **30**, 679-84 (1986).
166. Schenk, P.W. *et al.* Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients. *Mol Psychiatry* **13**, 597-605 (2008).
167. Morinobu, S. *et al.* Effects of genetic defects in the CYP2C19 gene on the N-demethylation of imipramine, and clinical outcome of imipramine therapy. *Psychiatry Clin Neurosci* **51**, 253-7 (1997).
168. Koyama, E. *et al.* Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients. *J Clin Psychopharmacol* **16**, 286-93 (1996).
169. Sindrup, S.H., Brosen, K. & Gram, L.F. Nonlinear kinetics of imipramine in low and medium plasma level ranges. *Ther Drug Monit* **12**, 445-9 (1990).
170. Skjelbo, E., Gram, L.F. & Brosen, K. The N-demethylation of imipramine correlates with the oxidation of S-mephenytoin (S/R-ratio). A population study. *Br J Clin Pharmacol* **35**, 331-4 (1993).
171. Skjelbo, E., Brosen, K., Hallas, J. & Gram, L.F. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. *Clin Pharmacol Ther* **49**, 18-23 (1991).
172. Madsen, H., Rasmussen, B.B. & Brosen, K. Imipramine demethylation in vivo: impact of CYP1A2, CYP2C19, and CYP3A4. *Clin Pharmacol Ther* **61**, 319-24 (1997).
173. Kirchheiner, J. *et al.* Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics. *J Clin Psychopharmacol* **23**, 459-66 (2003).
174. Kirchheiner, J., Sasse, J., Meineke, I., Roots, I. & Brockmoller, J. Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity. *Pharmacogenetics* **13**, 721-8 (2003).
175. Eap, C.B. *et al.* Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients. *Ther Drug Monit* **22**, 209-14 (2000).
176. Baumann, P. *et al.* The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. *Pharmacopsychiatry* **37**, 243-65 (2004).
177. Baumann, P. *et al.* Therapeutic monitoring of psychotropic drugs: an outline of the AGNP-TDM expert group consensus guideline. *Ther Drug Monit* **26**, 167-70 (2004).
178. Johnson, J.A. *et al.* Implementing Personalized Medicine: Development of a Cost-Effective Customized Pharmacogenetics Genotyping Array. *Clin Pharmacol Ther* (2012).